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Introduction
Psoriasis 
Psoriasis is a very common chronic disease affecting approximately 2% of the 
population worldwide. Males and females are equally affected. Psoriasis can present 
at any age, but a bimodal distribution of age at onset is seen with a large peak 
between 15 and 30 years and a smaller peak at 50-60 years.1 The pathogenesis of 
psoriasis is complex and concepts on the etiology have changed over the years. 
Studies from the 1970s provided evidence for a T-cell mediated skin disease.2;3 
Nowadays psoriasis is conceptualized as an immune mediated disease caused by 
many interactions between immune cells and keratinocytes, proinflammatory 
cytokines and chemical mediators.4-6 Classic linkage analyses and genome wide 
association studies have identified different genes associated with psoriasis. 
Population studies clearly indicate that the incidence of psoriasis is higher among 
first-degree and second-degree relatives of patients compared to the general 
population. The strongest association was observed in the psoriasis susceptibility 1 
region (PSORS1), which probably accounts for 35-50% of the heritability of the 
disease.7 Other psoriatic gene variants include the genes encoding the interleukin-23 
receptor (IL23R) and its ligand (IL12B).8 Also, an association between a high copy 
number of beta-defensins on chromosome 8p21.1 and an increased risk of psoriasis 
has been reported.9 
Psoriasis is characterized by sharply demarcated erythematous plaques covered 
with silvery white scaling (Figure 1). The most common type of psoriasis is psoriasis 
vulgaris, with symmetrically distributed plaques on the extensor sites of elbows, 
Figure 1  Classical presentation of psoriasis vulgaris with thick, sharply demarcated 
erythematosquamous plaques on the extensor site of an elbow and on the 
knee.
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Eczematous disease
Atopic dermatitis
Atopic dermatitis (AD) is a very common chronic relapsing inflammatory skin disease 
that occurs at any age, but usually starts before the age of 5 years. The prevalence of 
AD has doubled in industrialized countries in the past decades; 15-30% of children 
and 2-10% of adults are affected.23 Atopic dermatitis is a multifactorial disease arising 
as a result of the interaction of many genes with environmental factors (e.g. allergens 
and microbes) leading to an imbalance in the immune system and disruption of 
barrier function. In the majority of patients with AD elevated levels of total and allergen 
specific IgE can be detected. The acute phase of AD is characterized by a Th2-cell 
response which leads to increased cytokine production of interleukin (IL)-4, IL-5 and 
IL-13.24 In chronic atopic dermatitis, there is a shift from a single Th2 cell response to 
an environment of Th2 cell and Th1 cell type response. Many candidate genes 
encoding for cytokines involved in the Th2 cell response, e.g. IL-4, IL-5 and IL13 were 
identified on chromosome 5q31-33, 3q21 and 3p26.23;25 
 The disrupted skin barrier in AD allows penetration of microbes, allergens and 
irritants, leading to allergen sensitization and inflammation. In the past years, a strong 
association between mutations in the gene encoding filaggrin (FLG) and AD was 
observed in different populations. Filaggrin is a key protein in epidermal differentia-
tion and contributes to the keratin cytoskeleton; mutations in the gene coding for 
filaggrin results in diminished epidermal barrier function.26;27 Clinically, atopic 
dermatitis is characterized by itchy erythematous papules and plaques. In childhood, 
lesions are usually seen on the face, scalp and extensor surfaces of the extremities. 
Any cutaneous site can be affected, but the diaper area is often spared. During 
childhood, lesions favor the distal extremities, the poplitial flexures and posterior 
neck. In adults, AD is seen predominantly in a flexural distribution (Figure 2), but 
extensive areas of skin may be involved. Some adults present with a head neck 
knees, scalp and lumbosacral region. Psoriasis inversa involves skin folds of the 
axillary, inframammary, genital, intergluteal and perianal skin. Scaling in these areas 
is minimal. Other types of psoriasis are guttate psoriasis, generalized pustular 
psoriasis (von Zumbusch) and palmoplantar pustulosis. Associated features of 
psoriasis occur at the nails and joints. Nail psoriasis (psoriasis unguium) is common 
and is found in 20-50% of patients with psoriasis.10 Typical signs of nail changes are 
nail pitting, subungual hyperkeratosis, distal onycholysis and oil spots. The joints are 
affected in 10-20% of patients with psoriasis.11;12 In general, the classical psoriatic 
arthritis may consist of oligoarthritis, distal interphalangeal joint involvement, dactylitis 
and calcaneal enthesitis. 
    
Different treatment options exist for psoriasis (Table 1.) Topical therapy is the mainstay 
of treatment for psoriasis, especially in patients with mild disease. First line therapeutic 
modalities include topical corticosteroids and vitamin D analogues. Second line 
treatments are ditranol and coal tar ointments. In case of moderate or severe psoriasis 
phototherapy can be applied. Types of phototherapy used in psoriasis are 
narrow-band UVB and psoralen-UVA (PUVA).  When topical therapies or photo(chemo)
therapy are not effective, fail to induce long-term remission or are contra-indicated, 
systemic treatments can be used. Systemic treatments include methotrexate, 
retinoids, cyclosporine, fumaric acid esters and the recently introduced ‘biologics’. 
Some of these therapies are potential carcinogenic (e.g. PUVA and cyclosporin) and 
therefore, patients treated with these therapies may have an increased risk of cancer, 
such as non melanoma skin cancer and lymphomas.13-16 
 Studies that investigated the risk of cancer in patients with psoriasis showed an 
increased risk of cancer, especially non-melanoma skin cancer.17-22 The majority of 
these patients had been treated with potential carcinogenic therapies and therefore, 
it is not possible to discriminate between a possible increased intrinsic risk of cancer 
in patients with psoriasis and the effect of these therapies. 
Table 1  Treatment modalities for psoriasis.
Topical therapy Photoherapy Systemic therapy
Emollients UVB Methotrexate
Corticosteroids PUVA Cyclosporine
Vitamin D analogues  Retinoids
Coal tar  Fumaric acid esters
Ditranol  Biologics
Figure 2  Erythematous papules, plaques and excoriations in the flexural sites of the 
knees in a patient with atopic dermatitis and lichenification in the elbow.
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molecular weight molecules (haptens). ACD is characterized by two phases: the 
induction phase and the elicitation phase. After the first contact of the skin, the hapten 
is taken up by cutaneous dendritic cells, which migrate to regional lymph nodes. 
Contact of these dendritic cells with hapten-specific T-cells result in differentiation of 
T-memory cells. Challenge of sensitized individuals with the same hapten will result 
in elicitation of the inflammatory reaction after 48-72 hours by activation of the 
T-memory cells (elicitation phase). The most common causes of ACD are metals 
(nickel and chromate), cosmetics (preservatives, perfumes), cloths (dyes), drugs 
(active ingredient, preservative or vehicle) and plants.33  
 In irritant contact dermatitis the irritant has a direct toxic effect on the keratinocytes, 
leading to impairment of the barrier function.32 Damage to the epithelial cells leads to 
release of IL-1α by keratinocytes, which in turn stimulates other keratinocytes and 
fibroblast to produce more pro-inflammatory cytokines, such as IL-1α, IL-α, IL-6, IL-8 en 
TNF-α.32 Substances that are dehydrating or oxidizing agents or keratin solvents may 
be irritants. The effects of irritants are related to the chemical properties of the irritants, 
the concentration and duration of exposure.32
Coal tar
Coal tar is one of the oldest topical treatments in dermatology and is well-established 
in the management of various skin diseases, especially psoriasis and eczema. The 
exact mechanism of action is unknown, but coal tar has anti-pruritic and anti-inflam-
matory effects.34 Two coal tar preparations are mainly used in dermatological practice: 
crude coal tar (pix lithantracis) and its alcoholic extract liquor carbonis detergens. In 
general, coal tar ointments are well tolerated, but short-term adverse effects, such as 
folliculitis and irritation can occur. Coal tar can cause a phototoxic reaction and 
therefore, it is recommended to avoid sun exposure during treatment. Other 
disadvantages of using coal tar are its messiness, staining and odour. Therefore, 
these products, especially crude coal tar, are mainly used at dermatological day-care 
units and in hospitalized patients (Figure 3). 
    
Long-term adverse effects include the potential increased risk of cancer. Coal tar is a 
complex mixture of more than 10,000 compounds, including high concentrations of 
polycyclic aromatic hydrocarbons (PAH).35 Some PAH, such as benzo(a)pyrene are 
classified as human carcinogens by the International Agency for Research on 
Cancer36, based on both animal studies37-39 and occupational studies38;40-42, that 
demonstrated increased risks for lung, skin and bladder cancer after PAH exposure. 
The carcinogenic potential of coal tar is an important reason for dermatologists to be 
reluctant to use this therapy. There is still considerable uncertainty about the carcino-
genicity of coal tar in dermatological practice, because clear evidence of an increased 
risk of cancer after coal tar therapy is lacking. 
dermatitis or chronic hand dermatitis. Intense pruritus and a dry scaly skin are observed 
in the majority of patients with AD. 
    
Because of the dry skin, the use of emollients is important in the treatment of AD. The 
use of ointments can reduce flares by improving the barrier function of the skin. 
Topical corticosteroids are first-line treatments in AD (Table 2). To reduce side effects 
mid-potency preparations are used. However, more potent corticosteroids may be 
required for lichenified plaques and lesions on the palms and soles. Second line 
treatments are calcineurin inhibitors and coal tar ointments. In case topical therapy 
is ineffective or in case of severe AD, phototherapy (narrow-band UVB of PUVA) 
or systemic therapies can be prescribed. Systemic corticosteroids or cyclosporin 
should be reserved for the treatment of severe, acute flares that fail to respond to 
intensive topical therapy. However, disease relapse may make discontinuation 
difficult. In case of chronic relapsing AD, immunosuppressive therapies, such as 
methotrexate, cyclosporin or azathioprine can be prescribed to stabilize the disease. 
Atopic dermatitis causes chronic stimulation of cells of the immune system, leading 
to randomly occurring pro-oncogenic mutations in actively dividing cells and may 
therefore lead to increased risk of cancer. In addition, patients with atopic dermatitis 
are treated with potential carcinogenic therapies. Several studies reported an 
increased risk of cancer in patients with atopic dermatitis.28-30 As several of these 
patients had been treated with systemic therapies, it is not possible to disentangle 
the effect of treatment on the risk of cancer in these studies. 
Contact dermatitis
Contact dermatitis can be divided in allergic contact dermatitis (ACD) and irritant 
contact dermatitis (ICD). It is the most common form of occupational skin disease.31. 
The acute phase is characterized by erythema, edema and vesicles, followed by 
dryness and scaling in the chronic phase. Allergic contact dermatitis is a T-cell-me-
diated inflammatory reaction which occurs after the exposure of susceptible 
individuals to sensitizing chemicals.32;33 These cutaneous antigens are generally low 
Table 2  Therapies for atopic dermatitis.
Topical therapy Photoherapy Systemic therapy
Emollients UVB Corticosteroids
Corticosteroids PUVA Cyclosporin
Calcineurin inhibitors  Methotrexate
Coal tar  Azathioprine
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exposures, whereas the use of coal tar in dermatological practice is limited to a much 
shorter duration of exposure.48;49
 Most of the studies in patients lacked sufficient numbers of patients, follow-up 
data or did not control for confounding factors (e.g. smoking and treatment).Therefore, 
more research is needed to provide valid risk estimates of the use of coal tar in 
patients with psoriasis or eczema. 
Aim and outline of the thesis
The main objective of this thesis was to investigate the risk of cancer after coal tar 
treatment in patients with psoriasis or eczema. For this purpose, we initiated a large 
historical cohort study: the LAte effects of coal Tar treatment in Eczema and psoriasis; 
the Radboud study (LATER study).
 Chapter 2 comprises a review on the use of coal tar in dermatology. An overview 
of the preparation, method of action and its current use in dermatology is presented. 
The second part of the review focuses on the possible carcinogenicity of coal tar.  
 In chapter 3 the results of a survey that was conducted among Dutch and 
Flemish dermatologists are presented. Dermatologists were invited to describe their 
treatment policy in psoriasis and eczema with special emphasis on the use of coal tar 
preparations. This study enabled us to evaluate the position of coal tar in the treatment 
of these skin diseases. 
 In chapter 4 we report the results of our large-scale cohort study in which the risk 
of non-melanoma skin cancer and organ tumours after coal tar treatment was 
assessed in patients with psoriasis or eczema. In the second part of chapter 4 we 
present the results of a case-control study on the risk of bladder cancer after coal tar 
treatment. 
 The risk of cancer in patients with psoriasis or eczema has been investigated in 
many studies. However, in these studies it was not possible to disentangle the effect 
of treatment on the risk of cancer. In Chapter 5 the results from a cohort study in 
which the risk of cancer in patients with psoriasis or eczema was compared to the 
general population are presented. By selecting a group of patients who were only 
treated with dermatocorticosteroids we were able to exclude the effect of potentially 
carcinogenic treatments on the risk of cancer. Also, subgroups of patients were 
selected to assess cancer risk in patients treated with potentially carcinogenic 
therapies, such as PUVA and systemic therapies. 
 In Chapter 6 we report the results of a toxicology study in which the uptake, 
bioavailability and bio-activation of PAH in patients with psoriasis was compared to 
healthy volunteers. Patients with psoriasis have an altered skin barrier and this could 
have implications for the carcinogenic potential of coal tar. Differences in dermal 
Only few studies have investigated the risk of cancer in patients treated with coal tar 
(Table 3). The majority of these studies did not observe an increased risk of cancer.19;43-46 
Only one study by Stern et al. reported an increased risk of non-melanoma skin cancer in 
patients treated with coal tar.47 Differences in cancer risks observed in occupational 
studies versus studies in patients may be explained by the frequency, level and 
duration of PAH exposure. Malignancies have occurred after prolonged occupational 
Figure 3  Crude coal tar is applied to the hands and feet of a patient with atopic 
dermatitis.
Table 3   Epidemiological studies that investigated the risk of (skin) cancer  
after coal tar treatment (with or without UVB) in patients with psoriasis 
and eczema.
Author Study design Study 
group
Therapy Outcome RR (95% CI)
Hannuksela-
Svahn19 
Nested case-
control
Psoriasis Goeckerman1 SCC2 1.5 (0.3-7.3)
NHL3 1.2 (0.1-16.8)
Pittelkow46 Historic cohort Psoriasis Goeckerman1 All cancers No increased 
risk
Maughan45 Historic cohort Eczema Goeckerman1 All cancers No increased 
risk
Jones43 Historic cohort Psoriasis Coal tar All cancers No increased 
risk
Stern47 Nested case-
control 
Psoriasis Coal tar and/or 
UVB
Skin 5.6 (1.9-16.2)
1 combination of coal tar with UVB
2 Squamous cell carcinoma
3 Non-Hodgkin lymphomas
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Introduction
Coal tar has been used in the treatment of skin diseases for many decades. However, 
some reluctance has evolved recently among dermatologists for several reasons, 
including the difficulty of obtaining coal tar preparations. In the Netherlands, many 
pharmacies are no longer able to prepare coal tar products, because of stringent 
rules from the Dutch government regarding the preparation of such products. Other 
disadvantages of using coal tar are its messiness, staining and odor. Owing to its 
staining of clothes and furniture, it is not always possible to use tar preparations at 
home. The most important reason for the reluctance to use coal tar is its potential 
carcinogenicity with dermatological use. Animal studies and studies in occupational 
settings showed an increased risk of non-melanoma skin cancer after chronic 
exposure to coal tar.1-5 In epidemiological studies on the dermatological use of coal 
tar, some revealed an increased risk of non-melanoma skin cancer6-8, while most 
studies did not .9-13 Studies that investigated the risk of internal tumors after coal tar 
treatment did not find any increased risk of cancer. However, there is still considerable 
uncertainty about the carcinogenicity of coal tar due to the lack of convincing results 
from large epidemiological studies with sufficient follow-up. Therefore, the question 
remains as to whether it is justified to abandon coal tar preparations. To answer this 
question, two comparisons must be made: the risk versus the efficacy of coal tar and 
the risks versus the efficacy of other therapies.
 In this paper, we present an overview of the characteristics of coal tar and its 
current use in dermatology. Emphasis is laid on the possible carcinogenicity of coal 
tar. Furthermore, we discuss the need for further research data on which to draw a 
well-founded conclusion about the use of coal tar in dermatological practice.
Method of preparation
Tars are products of the destructive distillation of organic materials. The most frequently 
used tar product in dermatology is coal tar. Other tar products are wood tar (pix 
liquida) and shale tar (ammonium bituminosulfonate). 
 Coal tar is obtained by heating coal in the absence of air. It contains more than 
10,000 compounds, but only a minor proportion of them have been identified. The 
composition of coal tar depends mainly on the temperature of distillation. High-tem-
perature coal tars (1000-1300ºC) have a higher polycyclic aromatic hydrocarbon 
(PAH) content than low-temperature coal tars (400-700ºC). 
 Medical pix lithantracis is produced by mixing two thirds of pitch from high 
temperature sources with one third of tar oils (obtained by fractional distillation at 
220-270ºC). Liquor carbonis detergens is obtained by the extraction of 20 grams of 
pix lithantracis with 100 ml of alcohol and the addition of 5 grams of polysorbate. 
Abstract
Coal tar is one of the oldest treatments for psoriasis and eczema. It has anti-inflam-
matory, antibacterial, antipruritic and antimitotic effects. The short-term side effects 
are folliculitis, irritation and contact allergy. Coal tar contains carcinogens. The carci-
nogenicity of coal tar has been shown in animal studies and studies in occupational 
settings. There is no clear evidence of an increased risk of skin tumors or internal 
tumors. Until now, most studies have been fairly small and they did not investigate the 
risk of coal tar alone, but the risk of coal tar combined with other therapies. New, 
well-designed, epidemiological studies are necessary to assess the risk of skin 
tumors and other malignancies after dermatological use of coal tar.
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(figure 1). Coal tar has good antipruritic activity and has proved very effective on 
eczema lesions.28 As it difficult to use tar preparations at home (especially pix 
lithantracis), these products are mainly used at dermatological day-care units and in 
hospitalized patients. An exception is liquor carbonis detergens that can also be 
used at home.
Other skin diseases
Owing to the antipruritic and anti-inflammatory activities, coal tar products are also 
used in the treatment of pustulosis palmoplantaris and prurigo simplex.19;29
 Wood tar is produced by the destructive distillation of several types of wood 
(birch, beech, pine or juniper). Shale tar is obtained by the destructive distillation of 
bituminous stone that contains deposits of fossilized fish.
Modes of action
The precise mechanism of action of coal tar on a molecular level is unknown. Coal tar 
has anti-inflammatory, antibacterial and antipruritic effects.14 At the start of coal tar 
treatment, hyperplasia of the skin is observed. Continued application of coal tar has 
a cytostatic effect that causes epidermal thinning.15;16 These changes in keratinisation 
have also been shown in mouse models. After the application of coal tar, changes 
occurred in the type of prekeratin. Furthermore, after the application of coal tar to 
mouse models, parakeratotic regions in the epidermis were replaced by orthokeratotic 
regions.17 Coal tar also has a photodynamic effect that makes the skin more sensitive 
to UV light.18;19 
Applications
Psoriasis 
Several local therapies are prescribed for the treatment of psoriasis. Corticosteroids 
and vitamin D3 analogues are applied as first-line therapies. Also tar products and 
dithranol are frequently prescribed. This can be concluded from a recent survey 
among dermatologists in the Netherlands and Belgian Flanders on treatment policies 
for psoriasis and eczema (Table 1).20 However, a proportion of the dermatologists, 
approximately 25%, reported that they had stopped or minimized their use of coal tar 
products. In many cases, patients showed unwillingness to accept or comply with 
this therapy owing to the risk of staining and possible irritation of the skin. 
 Several studies have shown the efficacy of coal tar in the treatment of psoriasis.21;22 
However, it is unclear how the efficacy of coal tar compares to the efficacy of other 
therapies, because only a few studies compared the efficacy of coal tar to an active 
therapy. One study on the efficacy of coal tar preparations compared to vitamin D3 
analogues observed similar efficacy after one month, whereas other studies found 
that vitamin D3 analogues gave better results.
23-25 When itching is extensive and 
first-line therapies show insufficient improvement, tar products are recommended 
alternative therapies.  
Eczema
Several local therapies are available for the treatment of eczema. Local cortico-
steroids are very effective and are frequently prescribed by dermatologists (Table 1). 
Over the past several years, calcineurin inhibitors have been applied to patients with 
eczema. These therapies have proved effective in adults and children.26;27 Some 
indications are present for the use of coal tar preparations in the treatment of eczema 
Table 1   The use of local therapies in the treatment of psoriasis and eczema 
reported by dermatologists in the Netherlands and Belgian Flanders.
 Dutch dermatologists 
(n=225)
Flemish dermatologists 
(n=150)
Local therapies Eczema (%) Psoriasis (%) Eczema (%) Psoriasis (%)
Corticosteroids 100 100 99 99
Vitamin D3 analogues - 100 - 100
Tar products* 72 41 49 60
Dithranol - 56 - 30
Calcineurin inhibitors 92 - 98 -
Data were collected in a survey among Dutch (n=360) and Flemish dermatologists (n=330).20 The response 
of Dutch dermatologists was 63.2% and of Flemish dermatologists 41%. *Tar products are pix lithantracis, 
liquor carbonis detergens and pix liquida. 
Figure 1  Coal tar treatment in a patient with eczema. (a) Coal tar is applied by a 
nurse. (b) After the application of coal tar, the areas are covered with 
dressings.
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Although several studies investigated the risk of cancer in patients with psoriasis and 
eczema, only a few studies specifically addressed the risk of cancer after coal tar 
treatment (as monotherapy or in combination with UVB). The results of these studies 
are summarized in table 2. 
 In two parallel small retrospective studies, data were collected from patients who 
had been hospitalized in the period 1950-1954 and had received treatment with coal 
tar and UVB (Goeckerman-regimen) for psoriasis (n=260) or eczema (n=305).12;13 
After 25 years the observed numbers of skin malignancies were compared to the 
expected numbers. Neither of the studies showed an increased risk of skin cancer 
after coal tar treatment. However, the treatment durations and dose levels of coal tar 
varied widely in the study populations and no adjustments were made for other 
therapies that patients may have received, such as PUVA, cyclosporin or methotrexate. 
 A case-control study by Stern et al. (1980) found an increased risk of skin cancer 
in patients with psoriasis who had been treated with coal tar for more than 90 months 
and had received more than 300 UV light treatments (odds ratio = 5.6; 95% CI: 
1.9-16.2).6 All patients were drawn from the PUVA cohort (n= 1,373 patients) and had 
therefore been treated with PUVA. 
 Jones et al. (1985) investigated the risk of skin cancer and internal tumors in 719 
patients with psoriasis.10 These patients had received coal tar therapy intermittently 
over a 10-year period. None of them had been treated with UVB, PUVA or cytotoxic 
therapies. No increased risk of (skin) cancer was found. 
 In 2000, Hannuksela-Svahn et al. published the results of a reasonably large 
cohort study9 in which the risk of cancer was estimated in 5,687 hospitalized patients 
with psoriasis. During follow-up (mean duration 14 years) 533 tumors were observed. 
The number of expected tumors (n = 425.8) was based on the nation-wide 
sex-specific and age-specific cancer incidence rates for Finland. The overall cancer 
incidence was increased (standardized incidence ratio (SIR): 1.3; 95% CI: 1.2-1.4). 
Increased risks were found for squamous cell carcinoma (SIR= 3.2; 95% CI: 2.3-4.4), 
non-Hodgkin lymphoma  (SIR= 2.2; 95% CI: 1.4-3.4), Hodgkin lymphoma (SIR= 3.3; 
95% CI: 1.4-6.4), laryngeal cancer (SIR= 2.9; 95% CI: 1.5-5.0), lung cancer (SIR= 1.5; 
95% CI: 1.2-1.8) and liver cancer (SIR= 1.5; 95% CI: 0.9-3.3). A nested case-control 
study did not show a significantly increased risk of squamous cell carcinoma (30 
cases and 137 controls; OR = 1.5; 95% CI: 0.3-7.3) or non-Hodgkin lymphoma (19 
cases and 110 controls; OR=1.2; 95% CI: 0.1-16.8) after treatment with the Goeckerman 
regimen.
 Several other studies investigated the risk of cancer in psoriasis and eczema 
patients regardless of specific therapies.38-45 A recent study by Olesen et al. (2005) on 
2,030 hospitalized patients with eczema revealed an increased risk of cancer 
(standardized morbidity ratio (SMR): 1.5; 95% CI: 1.2-1.9).44 This increased risk could 
almost entirely be explained by an increased risk of non-melanoma skin cancer 
Adverse effects
Short-term
Coal tar has several side-effects. Folliculitis can occur, especially when high 
concentrations are used (above 5%); a common location is the lower extremities.15 
Coal tar can cause irritation of the skin in patients with unstable forms of psoriasis, 
pustular or erythrodermic psoriasis. Another side-effect of coal tar is contact allergy, 
while cross-allergies may also arise between coal tar and wood tar.30-33 Coal tar can 
cause a phototoxic reaction (figure 2). Therefore it is recommended to avoid sun 
exposure during treatment with coal tar. The part of the UV spectrum that is 
responsible for this reaction is within the UVA-visible region (340-430 nm). Thus, it is 
possible to become sunburnt, because UVA penetrates glass.
Long-term
Coal tar contains several polycyclic aromatic hydrocarbons (PAH), such as benzo(a)
pyrene, benz(a)antracene and diben(a,h)anthracene. These PAH are metabolized 
into reactive metabolites by cytochrome P450-systems in the liver, skin and blood. 
The metabolites are able to bind to macromolecules, such as DNA. As a consequence, 
PAH-DNA adducts are formed. These adducts may be important in tumor initiation.34-
37 Carcinogenicity of PAHs has been shown in animal studies and in workers with 
chronic exposure to PAHs.1-5 However, studies in a dermatological setting showed 
conflicting results.6;9-13 Occupational exposure to PAH is usually of very long duration 
at a low concentration level, whereas in dermatological practice, exposure is high 
and short-term. Also, the uptake route is different: with dermatological use, PAH 
uptake mainly occurs via the skin, while in occupational settings, the uptake route 
can also include the respiratory system. Such differences in PAH exposure levels and 
uptake routes may explain the variation in results found in studies on the risk of cancer 
after exposure to coal tar.
Figure 2  Phototoxic reaction caused by coal tar.
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Discussion
So far, there is no conclusive evidence of the carcinogenicity of coal tar in 
dermatological practice. Most of the studies were too small and lacked power to 
detect small increased risks. Although Hannuksela-Svahn et al. studied a large 
cohort, they did not control for other risk factors, such as smoking, sun exposure and 
occupational exposure to PAHs.9 It would be worthwhile for future studies to include 
a large number of patients with sufficiently long follow-up and to control for other risk 
factors. 
 An important risk factor in patients with psoriasis or eczema may be an impaired 
immune system. Theoretically it is possible that the indication for therapy involves an 
increased risk, not the therapy itself. However, several studies suggested that atopy 
is a protective factor for cancer.46 In most studies, atopy seemed to protect for the 
development of childhood gliomas and leukemias. Furthermore, most studies 
showed an inverse relation between atopy and pancreas cancer. No clear explanation 
has been put forward for the possible protective role of atopy in the development of 
tumors. Perhaps hyperreactivity of the immune system leads to increased immune 
surveillance. However, atopy causes chronic inflammation that in turn causes damage 
to tissues. The result is cell proliferation that could lead to an increased risk of cancer.
 It is important that future studies not only investigate the risk of skin cancer, but 
also the risk of internal malignancies. PAH are able to penetrate the skin, which leads 
to systemic absorption.47-49 As described earlier, cytochrome P450 enzymes 
metabolize PAHs into reactive metabolites. Many polymorphisms of cytochrome 
P450 enzymes have been described. These polymorphisms lead to variation in 
activity of enzymes involved in the metabolisation of PAH, such as aryl hydrocarbon 
hydroxylase and glutathione S-transferase.50;51 Therefore, a subgroup of patients may 
be more susceptible to the development of cancer after coal tar treatment. Future 
studies on the role of these polymorphisms in patients with psoriasis or eczema are 
needed to provide new insight into the risk of cancer after coal tar treatment.
In 2004, a large historical cohort study (the LATER-study: “Late effects of coal tar 
treatment in eczema and psoriasis; the Radboud study”) was started in the 
Netherlands. In this study 10,000 patients with psoriasis or eczema, diagnosed 
between 1960 and 1990, were included. This study investigates whether psoriasis or 
eczema patients who received coal tar treatment have an increased risk of developing 
cancer compared to patients who did not receive coal tar and compared to the 
general population. Data from these patients were collected from medical records 
and via questionnaires. Subsequently, linkage with the Netherlands Cancer Registry 
was conducted to assess the cancer incidence in this cohort. The results of this large 
study are expected in 2008.  
(SMR: 2.4; 95% CI: 1.4-3.9). No cases of melanoma were detected during the relatively 
short follow-up period; the increased risk of non-melanoma skin cancer could partly 
be explained by detection bias. The skin of patients with chronic eczema is often 
examined by dermatologists and this may increase the chance of discovering skin 
cancer compared to individuals in the general population. 
 Bofetta et al. (2001) conducted a similar cohort study on 9,773 hospitalized 
psoriasis patients.40 An overall increased risk of cancer was found (SIR: 1.37; 95% CI: 
1.28-1.47). This study did not only show an increased risk of non-melanoma skin 
cancer (SIR: 2.46; 95% CI: 1.82-3.27), but also increased risks for other types of 
cancer were found: pharynx (SIR: 2.80; 95% CI: 1.96-3.87), liver (SIR: 1.91; 95% CI: 
1.28-2.74), pancreas (SIR: 1.56; 95% CI: 1.02-2.23), lung (SIR: 2.13; 95% CI: 1.71-2.61), 
vulva (SIR: 3.24; 95% CI: 1.18-7.06), bladder (1.43; 95% CI: 1.03-1.92) and kidney (SIR: 
1.56; 95% CI: 1.04-2.25). The study showed a decreased risk of melanoma (SIR: 0.32; 
95% CI: 0.10-0.74). These two studies only included a highly selected population of 
psoriasis and eczema patients, i.e. all patients were hospitalized. 
Table 2   Epidemiological studies on the risk of (skin) cancer after coal tar 
treatment (with or without UVB) in patients with psoriasis or eczema.
Author Type of study Psoriasis 
or  
eczema
Therapy Outcome RR (95% CI)
Hannuksela-
Svahn et al.9
nested  
case-control
psoriasis Goeckerman 
regimen
squamous cell 
carcinoma
1.5 (0.3-7.3)
non Hodgkin’s 
lymphoma
1.2 (0.1-16.8)
Pittelkow  
et al.13
historic cohort psoriasis Goeckerman 
regimen
all skin cancers no increased risk
internal tumors no increased risk
Maughan  
et al.12
historic cohort eczema Goeckerman 
regimen
all skin cancers no increased risk
internal tumors no increased risk
Jones et al.10 historic cohort psoriasis Coal tar all cancers no increased risk
Stern et al.6 nested  
case-control  
(PUVA study)
psoriasis Coal tar  
and/or UVB
skin 5.6 (1.9-16.2)
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Introduction
Psoriasis and eczema are chronic skin diseases, which often require years of 
treatment. Many therapies are available for these dermatoses. In recent years, new 
topical therapies (e.g. calcineurin inhibitors) and systemic therapies (e.g. biologicals) 
have been introduced. Coal tar has been a well-established therapy for psoriasis and 
eczema in the past decades, but some reluctance to use coal tar has evolved among 
dermatologists over the past years. One of the reasons for this reluctance is the 
suspicion of an increased risk of cancer after coal tar treatment in dermatological 
practice. This suspicion is based on animal studies and studies in the occupational 
setting showing an increased risk of nonmelanoma skin cancer after chronic exposure 
to coal tar.1-5 However, the results of epidemiologic studies on dermatological use of 
coal tar are conflicting. One study showed an increased risk of nonmelanoma skin 
cancer after coal tar treatment,6 but other studies did not reveal an increased risk.7-11 
The risk of other types of cancer is unknown. Because of a lack of large epidemio-
logical studies with long-term follow-up that specifically investigated the (late) side 
effects of coal tar treatment, uncertainty about the carcinogenicity of coal tar with 
dermatological use remains. For this reason the LATER-study (“Late effects of coal 
tar treatment in eczema and psoriasis; the Radboud study”) started in November 
2003 in the Netherlands. In this study 10,000 patients diagnosed with psoriasis or 
eczema before 1990 will be included and the risk of cancer after coal tar treatment will 
be evaluated.
 Because of the possible carcinogenicity and several additional reasons (e.g., 
use is unpleasant for patients, doubts on efficacy and difficulties in obtaining coal tar 
from pharmacies) the use of coal tar in the dermatological practice has decreased 
over the past years. A survey was conducted among Dutch and Flemish dermatologists 
with special emphasis on the use of coal tar in order to find out the position of coal 
tar in the treatment of skin diseases. The study was carried out in two countries to get 
an impression on the variation between countries with respect to use of coal tar. This 
survey was conducted as part of the LATER- study. 
Methods
A questionnaire was developed and pilot-tested among three expert dermatologists 
(two from the Netherlands and one from Flanders). All dermatologists were asked to 
describe their treatment policy in case of mild/moderate psoriasis, severe psoriasis, 
mild/moderate eczema and severe eczema. For these questions, a list with topical, 
photo-, and oral therapies was provided and dermatologists could mark whether or 
not they used a listed therapy. In addition, dermatologists could describe therapies 
Abstract
Today, many therapies are available for the treatment of psoriasis and eczema. One 
of the oldest topical therapies is coal tar. Coal tar has been used for decades, but 
over the past years, the use of coal tar has decreased for several reasons, including 
the supposed carcinogenicity of coal tar. We investigated the current and past 
treatment policy for psoriasis and eczema with special emphasis on the use of tar 
products. A postal survey was conducted among all dermatologists in two European 
countries: the Netherlands (n=360) and the Flemish speaking part of Belgium 
(Flanders) (n=328). This study was conducted as part of the ongoing LATER-study 
(“Late effects of coal tar treatment in eczema and psoriasis; the Radboud study”). All 
practising dermatologists received a questionnaire. Dermatologists were asked to 
describe their treatment policy in mild/moderate psoriasis, severe psoriasis, mild/
moderate eczema and severe eczema. The response rate to the questionnaire was 
62.5% for the Dutch dermatologists and 45.7% for the Flemish dermatologists. Almost 
all dermatologists prescribe topical corticosteroids. In eczema, most of the 
dermatologists prescribe the recently introduced calcineurin inhibitors (95%). Coal tar 
is a second choice topical therapy. Dutch dermatologists mainly use tar in the 
treatment of eczema (72% vs. 48% in Flanders), whereas in Flanders tar is mainly 
prescribed in psoriasis (60% vs. 41% in Holland). Flemish dermatologists very 
frequently prescribe PUVA in psoriasis (93% vs. 63%). 
 Topical treatment, especially topical corticosteroids, is the mainstay in psoriasis 
and eczema. Coal tar still is an important (second choice) therapy for the topical 
treatment of psoriasis and eczema, but its use varies from country to country.  Despite 
the carcinogenicity of PUVA, this photochemotherapy is frequently prescribed by 
dermatologists, mainly in Flanders. 
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dermatologists prescribe solutio carbonis detergens in both mild/moderate psoriasis 
and severe psoriasis (68%), while a considerable part of the Dutch dermatologists 
prescribe this coal tar product only to patients with mild/moderate psoriasis (42%). 
Pix liquida (wood tar) is not used by Flemish dermatologists and is used by only 5% 
of the Dutch dermatologists. Dermatologists practising in a general hospital treat 
patients less frequently with tar products than their colleagues from the university 
hospitals or private clinics (44% vs. 52% and 58%). Next to coal tar, dithranol is 
applied as a second choice therapy. Overall, 46% of all dermatologists use dithranol. 
It is more frequently applied by Dutch dermatologists compared to Flemish 
dermatologists (56% vs. 30%). Dutch dermatologists prefer to use dithranol in both 
mild/moderate psoriasis and severe psoriasis (52% compared to 41% of the Flemish 
dermatologists), whereas the Flemish dermatologists prescribe dithranol more 
frequently to patients with mild psoriasis (25% vs. 15%). Dermatologists in university 
hospitals and in general hospitals prescribe dithranol more often than the 
dermatologists practising in private clinics (62% and 53% vs. 17%).
 When topical therapies appear to be insufficiently effective or when skin lesions 
are increasing, almost all dermatologists will treat their patients with phototherapy. 
Flemish dermatologists prefer to use PUVA (93% vs. 63% of the Dutch dermatologists) 
whereas the Dutch dermatologists prefer to use UVB as first-choice phototherapy 
(99% compared to 83% of the Flemish dermatologists). In both countries, the majority 
of the dermatologists apply UVB in both severe psoriasis and mild/moderate psoriasis 
(79%). In case of PUVA, a small majority of dermatologists apply this photochemo-
therapy in severe psoriasis as well as in mild/moderate psoriasis (58%); a considerable 
part of dermatologists only use this therapy in patients with severe psoriasis (41%). 
 When psoriasis is resistant to topical therapy or phototherapy, dermatologists 
can apply oral therapies. Several oral therapies are available for the treatment of 
psoriasis. In the Netherlands first choice oral therapies include methotrexate and 
retinoids (81% and 76%) whereas in Flanders first choice therapies are retinoids and 
cyclosporine (83% and 70%). Fumarates are less frequently used compared to other 
oral therapies. In addition to the above-mentioned therapies, approximately 15% of 
the Dutch and Flemish dermatologists reported to apply therapies that were not listed 
in the questionnaire. Most frequently reported were emollients, salicylic acid 
containing ointments and Dovobet® (containing betamethasone dipropionate and 
calcipotriol hydrate). The recently introduced biologicals (e.g., infliximab and 
efalizumab) were mentioned by 6 dermatologists. Because these agents were not 
registered and reimbursed at the time of this survey, these agents are likely to be 
prescribed within a clinical trial setting.
that he/she uses and that were not recorded in the list of questions. They were also 
asked to list therapies that they had prescribed in the past but stopped prescribing, 
including the reason(s) and year of stopping. Finally, they were asked about 
prescriptions of topical therapies in the case of pregnant patients with psoriasis or 
eczema. In this questionnaire the overall terms ‘psoriasis’ and ‘eczema’ were used. 
As a consequence, these terms included all different types of psoriasis and eczema. 
 The questionnaires were sent to all practising dermatologists in the Netherlands 
(N=360) and Flanders (N=328) who were registered as a member of the Dutch or 
Belgian Association for Dermatology and Venereology. The questionnaire was 
accompanied by an invitational letter. In this letter we shortly introduced the ongoing 
LATER-study. We explained that as part of this study (that estimates the risk of cancer 
after coal tar treatment) we were interested in the position of coal tar in the spectrum 
of treatment modalities for psoriasis and eczema. 
 The invitational letters and questionnaires were mailed to the dermatologists in 
the summer of 2004. After three weeks, a reminder was sent. All collected data were 
summarised descriptively using the statistical software program SPSS version 12.
Results
A total of 236 questionnaires were returned by Dutch dermatologists (response rate 
62.5%) and 153 questionnaires by Flemish dermatologists (response rate 45.7%). 
Fourteen dermatologists were retired or left the questionnaire blank and were 
therefore excluded from the study.
 Large differences exist in the work setting of Dutch and Flemish dermatologists; 
the majority of Dutch dermatologists practise in a general hospital (77%) while most 
Flemish dermatologists practise in a private clinic (51%). The percentage of 
dermatologists practising in a university hospital is about the same in both countries 
(16% in the Netherlands, 17% in Flanders). 
 
Treatment of psoriasis (Table 1)
As expected, almost all dermatologists initially prescribe topical corticosteroids and 
vitamin D3 analogues to patients with psoriasis. The majority of dermatologists (91%) 
use class 3 corticosteroids (e.g., bethametasone dipropionate) for patients with mild/
moderate psoriasis. In case of severe psoriasis, dermatologists prefer class 4 corti-
costeroids (e.g., clobetasol dipropionate) (93%). In addition to corticosteroids and 
vitamin D3 analogues, 49% of all dermatologists also apply tar products in patients 
with psoriasis. Overall, the most frequently used tar product is solutio carbonis 
detergens; the Flemish dermatologists apply this much more frequently compared to 
Dutch dermatologists (56% vs. 30%, respectively). The majority of the Flemish 
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Treatment of eczema (Table 2)
Similar to psoriasis, topical steroids are the first choice topical therapy in eczema. 
Class 2 corticosteroids are mostly prescribed to patients with mild to moderate 
eczema (91%). In severe eczema, dermatologists prefer class 3 corticosteroids (89%). 
Other first choice therapies include calcineurin-inhibitors tacrolimus (Protopic®) and 
pimecrolimus (Elidel®). Dutch dermatologists prefer the use of tacrolimus (92% and 
40%, respectively) while Flemish dermatologists appear to have no preference (96% 
vs. 93%). Dutch dermatologists use tar products more frequently compared to 
Flemish dermatologists (72% vs. 48%). As with psoriasis, the most frequently used tar 
Table 1   Therapies used in the treatment of psoriasis reported by dermatologists 
in the Netherlands and Flanders by severeness and country.
 
 
 
 
All Dutch and Flemish
dermatologists (n = 375)
Dermatologists from
the Netherlands (n = 225)
Dermatologists from
Flanders ( n = 150)
Total of
dermatologists
Only 
mild/
moderate
psoriasis
Only 
severe
psoriasis
Both Total of
dermatologists
Only 
mild/
moderate
psoriasis
Only 
severe
psoriasis
Both Total of
dermatologists
Only 
mild/
moderate
psoriasis
Only 
severe
psoriasis
Both
1  Therapy % (n) % % % % (n) % % % % (n) % % %
Topical
    Topical corticosteroids 100 (374)   3   1 96 100 (225)  4  - 96  99 (149)   2   1 97
    Vitamin D3 analogues 100 (374) 16  - 84 100 (224) 19  - 81 100 (150) 12   - 88
    Tar products  49 (183) 23 15 62 41 (93) 22 24 54 60 (90) 23   7 70
Pix lithantracis1         20 (73) 12 43 45 24 (54) 11 43 46 14 (19) 16 42 42
1.1  Solutio carbonis detergens2 40 (151) 33 11 56 30 (67) 42 18 40 56 (84) 26   6 68
Pix liquida (wood tar) 3 (11)   9 45 46   5 (11)   9 45 46 -  -   -   -
    Dithranol 46 (169) 18 33 49 56 (125) 15 33 52 30 (44) 25 34 41
Phototherapy
UVB 93 (346)   6 15 79 99 (222)   6 12 82 83 (124)   7 21 72
PUVA 75 (280)   1 41 58 63 (141)   1 46 53 93 (139)   1 35 64
Oral
Methotrexate 72 (269)   1 72 27 81 (182)   1 67 32        58 (87)   2 83 15
Retinoids 80 (297)   3 53 44 76 (172)   3 47 50 83 (125)   4 61 35
Cyclosporine 66 (247)   1 74 25 63 (142)   1 68 31 70 (105)   1 83 16
Fumarates 28 (106)   5 50 45 43 (96)   5 48 47 7 (10)   - 70 30
The first column shows the percentages and numbers of dermatologists prescribing specific therapies. The 
next columns shows the percentages of the prescribing dermatologists who prescribe the therapy only in 
case of mild/moderate psoriasis, only in severe psoriasis or in both mild/moderate psoriasis and severe 
psoriasis. 
1   Pix lithantracis is most frequently used in concentrations of 1.5%-5%; 1 g of 1.5% or 5% pix lithantracis 
contains 15 mg or 50 mg tar, respectively.
2   Solutio carbonis detergens is most frequently used in concentrations of 10%; 1 g of 10% solution carbonis 
detergens contains approximately 16 mg tar.
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 The next step in the treatment of eczema is phototherapy. In both countries, UVB 
appears to be the first-choice phototherapy. UVB is frequently applied by Dutch 
dermatologists in both mild/moderate eczema and severe eczema (65%) while 
Flemish dermatologists prefer to use UVB only in patients with severe eczema (61%). 
Similar to psoriasis, PUVA is more frequently used by Flemish dermatologists than by 
their Dutch colleagues (52% vs. 31%). In both countries, it is mainly prescribed in 
patients with severe eczema. In patients with severe eczema or when topical or 
phototherapy is not effective, oral therapies are applied. In both countries, 
dermatologists prescribe cyclosporine and oral corticosteroids approximately as 
many times (62% and 59%, respectively). The most frequently reported therapies that 
were not listed in the questionnaire were emollients, oral/topical antibiotics and 
antihistamines.
product is solutio carbonis detergens. In both countries, most dermatologists apply 
this therapy in both mild/moderate eczema and severe eczema (55%), while pix 
lithantracis is mainly prescribed to patients with severe eczema (60%). In contrast to 
psoriasis, Dutch dermatologists practising in a general hospital prescribe tar products 
more often than their colleagues practising in a university hospital or a private clinic 
(74% vs. 69% and 63%). In Flanders, tar products are more frequently prescribed in a 
private clinic compared to a university or a general hospital (56% vs. 40% and 40%). 
Table 2   Therapies used in the treatment of eczema reported by dermatologists 
in the Netherlands and Flanders by severeness and country.
 
 
 
 
All Dutch and Flemisch
dermatologists (n = 375)
Dermatologists from 
the Netherlands (n = 225) 
Dermatologists from 
Flanders ( n = 150) 
Total of
dermatologists
Mild/
moderate
eczema
Severe
eczema
Both Total of
dermatologists
Mild/
moderate
eczema
Severe
eczema
Both Total of
dermatologists
Mild/
moderate
eczema
Severe
eczema
 Both
Therapy % (n) % % % % (n) % % % % (n) % % %
Topical     
    Topical corticosteroids 100 (374) 1 0 99 100 (225) 0 0 100 99 (149) 1 1 98
    Calineurin inhibitors 95 (355) 21 8 71 92 (208) 25 9 66 98 (147) 16 6 78
  Coal tar 63 (234) 20 11 69 72 (163) 19 9 72 48 (71) 22 16 62
    Pix lithantracis1 30 (109) 5 60 35 38 (86) 6 59 35 16 (23) 4 31 35
    Solutio carbonis detergens2 59 (218) 36 9 55 66 (149) 38 7 55 47 (69) 33 13 54
    Pix liquida 9 (34) 21 35 44 13 (30) 13 37 50 3 (4) 75 25 0
Phototherapy     
    UVB 82 (308) 2 42 56 91 (205) 2 33 65 69 (103) 1 61 38
    PUVA 39 (146) 2 71 27 31 (69) 3 71 26 52 (77) 1 72 27
Oral     
    Corticosteroids 59 (222) 1 87 12 66 (148) 1 86 13 50 (74) 0 89 11
    Cyclosporine 62 (234) 1 86 13 65 (146) 1 84 15 59 (88) 1 91 8
The first column shows the percentages and numbers of dermatologists prescribing specific therapies. The 
next columns shows the percentages of the prescribing dermatologists who prescribe the therapy only in 
case of mild/moderate eczema, only in severe eczema or in both mild/moderate eczema and severe 
eczema.
1   Pix lithantracis is most frequently used in concentrations of 1.5%-5%; 1 g of 1.5% or 5% pix lithantracis 
contains 15 mg or 50 mg tar, respectively.
2   Solutio carbonis detergens is most frequently used in a concentration of 10%; 1 g of 10% solution carbonis 
detergens contains approximately 16 mg tar.
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Discussion
In psoriasis, topical corticosteroids and vitamin D3 analogues are applied by almost 
all dermatologists. Tar products and dithranol are second choice therapies. This is in 
accordance with European surveys conducted in the past among patients with 
psoriasis.12-15 American surveys also show that topical corticosteroids and vitamin D3 
analogues are the most frequently prescribed topical therapies.16;17
 Phototherapy is mainly applied in patients with severe psoriasis or when topical 
therapy is not effective. In the past years several studies showed an increased risk of 
nonmelanoma skin cancer after PUVA-therapy.18-21 Still, more than 60% of the Dutch 
dermatologists and even more than 90% of the Flemish dermatologists prescribe this 
photochemotherapy for psoriasis. PUVA and UVB have a comparable efficacy but 
the long-term safety of UVB therapy is more favourable.22 Almost all studies that 
investigated the risk of cancer after UVB therapy did not show an increased risk.23 
PUVA may be considered in case UVB treatment has an insufficient effect.24
 In case of oral therapy for the treatment of psoriasis, retinoids are frequently 
applied by dermatologists in both countries. In Flanders, it is the most frequently 
applied oral therapy. This is remarkable because of the moderate efficacy of retinoids 
as monotherapy in psoriasis vulgaris, the most common type of psoriasis.25-27 The 
guidelines of the Dutch Association for Dermatology and Venereology recommend 
that methotrexate, and not a retinoid, is the first choice oral therapy.22 Fumarates are 
the least frequently prescribed oral therapies by dermatologists, especially in 
Topical treatment in pregnant patients 
Most dermatologists are reluctant to prescribe tar products to pregnant women with 
psoriasis or eczema (Table 3). Topical corticosteroids appear to be the most 
prescribed treatment for psoriasis and eczema during pregnancy. A few dermatologists 
use dithranol when treating pregnant women with psoriasis or eczema.
Therapies used in the past
Approximately, one-third of all dermatologists reported using one or more therapies 
in the past which they less frequently, or not at all, apply nowadays (Table 4). The 
most frequently mentioned therapy was coal tar. Several reasons were given for 
stopping or minimizing the use of coal tar. Most frequently reported reasons were 1) 
the difficulty to obtain coal tar from the pharmacy (42 times) 2) the unpleasant use for 
patients (11 times) 3) possible carcinogenicity (10 times) and 4) difficulties to use tar 
at home (10 times). Other therapies that are no longer/less used by dermatologists 
are dithranol, with the main reason its unpleasant use for patients, cyclosporine and 
PUVA, both because of the adverse effects.
Table 3   Percentages of dermatologists prescribing topical therapies in pregnant 
women.
Yes, during the
whole pregnancy (%)
Yes, but not during
the 1st  trimester (%)
No (%)
Tar products   9   9 82
Dithranol   3   4 93
Corticosteroids 77 17   6
Table 4   Therapies no longer/less prescribed by Dutch and Flemish 
dermatologists.
Therapy Number of 
dermatologists
Most reported reason for stopping
Coal tar 92 difficulties in obtaining tar from pharmacies 
Dithranol 26 unpleasant use for patients 
Retinoids   6 unsatisfactory effect
Cyclosporine 12 adverse effects/carcinogenicity
Fumarates   2 unsatisfactory effect
Methotrexate   2 adverse effects, better alternatives
PUVA 9 adverse effects/carcinogenicity
Vitamin D3 analogues 3 unsatisfactory effect
Other 16                             -
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topical corticosteroids are prescribed during pregnancy while the safety of some 
preparations during pregnancy is questionable. According to the Swedish 
classification of risk of drug use during pregnancy and lactation, preparations like 
betamethasone, fluticasone and triamcinolone are classified in group C which means 
that the pharmacological action of the drug may have undesirable effects on the 
human fetus or newborn infant. However, when the duration and area of application 
are limited and a mild preparate is used, corticosteroids can be prescribed during 
pregnancy even in the first trimester of pregnancy.33
 The present study has indicated that a major part of dermatologists in two 
European countries still use tar products in the treatment of psoriasis and eczema. 
The variation between the Netherlands and Flanders with respect to the use of coal 
tar products is intriguing. However, no guidelines or treatment recommendation of 
the national or European dermatological societies are available, which explains the 
highly variable use of topical treatments in psoriasis and eczema, especially with 
respect to coal tar and dithranol.
 Despite the clear or suggested unfavourable effects, many dermatologists still 
prescribe coal tar preparations. So far coal tar remains an important therapy for 
psoriasis and eczema. Future research has to assess the risk of (late) side effects of 
coal tar and compare this to the risks of other therapies that are available for the 
treatment of these dermatoses.
Flanders. This oral therapy is not licensed in both the Netherlands and Flanders, 
which is probably the main reason for the limited use of fumarates.
As in psoriasis, in eczema, topical corticosteroids are prescribed by almost all 
dermatologists. The recently introduced calcineurin inhibitors are also frequently 
applied by both Dutch and Flemish dermatologists. The European Task Force on 
atopic dermatitis recommend topical corticosteroids as first choice therapy and they 
state that calcineurin inhibitors are useful second choice agents.28 The guidelines 
from the American Association of Dermatology on the treatment of atopic dermatitis 
also prescribe topical corticosteroids and calcineurin inhibitors as most useful 
agents.29 A major advantage of calcineurin inhibitors, compared to topical steroids, is 
that these agents do not cause skin atrophy.30;31 There is a theoretical risk of promotion 
of skin cancer because these agents modify the immunoregulatory function of the 
skin.31;32 These agents were introduced a few years ago. Therefore, results of 
epidemiologic studies with long-term follow up that have assessed the risk of (skin)
cancer after the use of calcineurin inhibitors are not available. So far, available data 
suggest that the use of calcineurin inhibitors is safe, but a definite place for these 
agents in the treatment for eczema has to be established.30
 The use of coal tar products is under discussion. Some dermatologists have 
stopped using it and other dermatologists still regard tar products as part of the 
therapeutic spectrum. The main reason for stopping is the difficulty to obtain coal tar 
preparations from the pharmacies. Due to stringent rules from the Dutch government 
for preparing coal tar products, many pharmacies are no longer capable of preparing 
these products. These rules are derived from the rules of the European Union 
concerning the protection of employees against the risk of exposure to carcinogen 
and mutagenic agents in the working place (rule 2004/37/EG). PAH are recorded as 
carcinogenic and mutagen agents by the European Union and therefore, exposure to 
these agents during work comes under these rules. Another reason is the difficulty of 
using tar at home. Because coal tar stains furniture and clothes, it is not always 
possible to use tar preparations at home. Another reason for stopping is the possible 
carcinogenicity of coal tar (but mentioned by no more than 10 dermatologists). 
Studies carried out so far on the long-term effects of coal tar in patients with psoriasis 
or eczema have shown conflicting results6-11 and therefore large-scale epidemiologic 
studies are needed that include a large number of patients and have sufficient 
follow-up. Studies conducted so far mainly focused on the risk of skin cancer after 
coal tar treatment. However, coal tar penetrates the skin, which leads to systemic 
absorption of PAH. Therefore it is important that future studies not only investigate the 
risk of skin cancer but also the risk of internal tumors after exposure to coal tar.
 Many dermatologists hesitate to prescribe coal tar preparations during 
pregnancy. Also dithranol is not frequently prescribed to pregnant women. In general, 
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Introduction
Coal tar is one of the oldest topical treatments in dermatology. It is well-established 
in the management of various skin diseases, especially psoriasis and eczema. Coal tar is 
a complex mixture of more than 10,000 compounds, including high concentrations of 
polycyclic aromatic hydrocarbons (PAH). Coal tar is obtained by heating coal in the 
absence of air. Medical pix lithantracis is produced by mixing two thirds of pitch of 
high temperature sources with one third of tar oils. Liquor carbonis detergens is 
obtained by extraction of 20 gram pix lithantracis with 100 ml alcohol and addition of 
5 gram polysorbate. In general, the use of pix lithantracis is restricted to a hospital or 
day-care setting, because of staining of furniture and clothes and the strong odor, but 
liquor carbonis detergens can be used at home. It is well-known that some PAH, such 
as benzo(a)pyrene and benz(a)antracene, are carcinogenic.1;2 Animal studies2-4 and 
occupational studies3;5-7 showed increased risks of lung and non-melanoma skin 
cancer after chronic exposure to coal tar. The risk of cancer after coal tar treatment in 
dermatological practice is still unclear because of the lack of large-scale observational 
studies. All studies performed so far lacked sufficient numbers of patients, follow-up 
data or data on potential risk factors, e.g. treatment, smoking, and sun exposure, to 
accurately estimate the risk of cancer after coal tar application.8-13 Despite the lack of 
clear evidence of an increased risk of cancer after dermatological use of coal tar, 
many dermatologists around the world have abandoned coal tar as a therapeutic 
option.14;15 Some dermatologists even consider the use of coal tar obsolete.16 However, 
several alternative therapies for psoriasis and eczema, such as psoralen plus 
ultraviolet light A (PUVA) and ultraviolet B are known or suspected carcinogens as 
well and therapies such as cyclosporine, methotrexate and topical calcineurin inhibitors 
may facilitate carcinogenesis by its immunosuppressive action. We therefore question 
whether it is justified to abandon coal tar before making a valid assessment of the risk 
of cancer. To assess the risk of cancer after coal tar treatment in patients with 
psoriasis or eczema, we initiated a large historical cohort study, the LATER study 
(LAte effects of coal Tar treatment in Eczema and psoriasis; the Radboud study). 
Subjects and methods
The LATER study was initiated in 2003. The cohort comprised patients diagnosed 
with psoriasis or eczema between 1960 and 1990 in one of three large hospitals in 
the Netherlands. These hospitals include two university hospitals and one teaching 
hospital. Between January 2004 and June 2006, over 300,000 medical records 
stored in the paper archives of the Departments of Dermatology at these hospitals 
were searched manually to identify eligible patients. A detailed description of data 
Abstract  
Coal tar is an effective treatment for psoriasis and eczema, but it contains several 
carcinogenic compounds. Occupational and animal studies have shown an increased 
risk of cancer after exposure to coal tar. Many dermatologists have abandoned this 
treatment for safety reasons, although the risk of cancer after coal tar in dermatological 
practice is unclear. This large cohort study included 13,200 patients with psoriasis 
and eczema. Information on skin disease and treatment, risk factors and cancer 
occurrence was retrieved from medical files, questionnaires and medical registries. 
Proportional Hazards regression was used to evaluate differences in cancer risk by 
treatment modality. Patients treated with coal tar were compared to a reference 
category of patients treated with dermatocorticosteroids (assumed to carry no 
increased cancer risk). The median exposure to coal tar ointments was six months 
(range 1-300 months). Coal tar did not increase the risk of non-skin malignancies 
(hazard ratio (HR) = 0.92;95% confidence interval (CI) = 0.78-1.09), or the risk of skin 
cancer (HR = 1.09;95%CI = 0.69-1.72). This study has sufficient power to show that 
coal tar treatment is not associated with an increased risk of cancer. These results 
indicate that coal tar can be maintained as a safe treatment in dermatological 
practice. 
60 61
Risk of cancer after coal tar treatment in patients with psoriasis or eczema Chapter 4.1
4
Data collection through questionnaires 
All patients with verified contact information (n=9,387) and 412 partners of the 
deceased patients were invited to participate in the study. They were sent an invitation 
letter, an information leaflet and a questionnaire. All subjects were asked for informed 
consent for participation in the study and for linkage of their personal data to medical 
registers. They were asked to fill out a detailed questionnaire concerning demographic 
factors, use of alcohol (yes vs no and number of glasses/day in past year), smoking 
habits (current/former/never and pack years), skin type, history of sunlight exposure 
(use of tanning beds [never, 1-4, 5-10, 11-20, 21-50, >50 times/year], residence in 
tropical areas [never, <1, 1-2, 3-5, 6-10 years]), occupational history (including history 
of outside occupation), detailed information on the skin disease and history of other 
(skin)diseases and cancer. Questionnaires were scanned, processed and data were 
stored in a database (Teleform®, Cardiff, Vista, CA). After three weeks, a reminder 
was sent. Questionnaires with missing data or unclear information were completed 
by telephone calls. Data from questionnaires were added to the data retrieved from 
the medical files. In case information from the questionnaires did not correspond with 
information from the medical files, information from the medical files was assumed to 
be superior. A total of 5,927 questionnaires were returned, corresponding with a 
response rate of 61%. 
Data on cancer occurrence through linkage with population-based 
registers
The occurrence of cancer, as assessed through information in the medical files and 
questionnaires, was supplemented by record linkage to the Netherlands Cancer 
Registry (NCR). The NCR has nation-wide coverage since 1989. At the time of linkage, 
cancer incidence data were complete until 2003. Linkage was performed for all living 
and deceased patients, except for those who explicitly refused (n=406). Although 
non-responders and deceased patients did not give explicit consent, linkage to the 
NCR is allowed using a strict privacy procedure.17 To assess cancer occurrence 
among patients who died before 1989, all deaths were linked to the Causes of Death 
Registry of Statistics Netherlands. This registry has been recording causes of death 
information in the Netherlands since 1901. 
 If information retrieved from the NCR did not correspond with the information in 
the questionnaires and/or medical files, the information from the NCR was assumed 
to be superior.
Statistical analysis
Multivariable proportional hazards regression models were used to estimate the 
relative risk of cancer after coal tar treatment. Follow-up for each patient was 
calculated as the time from date of diagnosis of psoriasis or eczema until date of 
collection is described below. The LATER study was approved by the Institution 
Review Boards of all three hospitals. 
Selection of patients and data collection from medical files
All patients included in this study had to be diagnosed with psoriasis or eczema. 
Furthermore, patients had to fulfil the following eligibility criteria: 1) The date of 
diagnosis of psoriasis or eczema should be between 1960 and 1990 to obtain 
sufficient follow-up for cancer to occur; and 2) the patients had to have visited a 
dermatologist at least thrice, to support the presumption that the skin disease was 
sufficiently severe to require medical treatment. A total of 14,009 patients met the 
eligibility criteria. Administrative data were recorded in a database. In addition, 
detailed information on the medical history was collected from the medical files. 
 Data on variables collected from the medical files were complete and of good 
quality for the majority of the variables. Information on therapies that patients received 
was available from the medical files. However, it was not possible to extract information 
on duration of the received therapies. Medical history and data on cancer occurrence 
during follow-up, especially non-skin cancer, were not always recorded in the medical 
files. This information was supplemented by questionnaires and linkages to the 
Netherlands Cancer Registry and Causes of Death Registry. Recent data on vital 
status were frequently unavailable in the medical files. This was supplemented by 
linkages to the Hospital Information Systems of the participating hospitals, the 
nationwide Dutch Municipal Personal Records Database and the Central Bureau of 
Genealogy (described below).
Updating information 
Figure 1 shows the labour-intensive stepwise procedure that was followed to update 
information on the place of residence and vital status. At the time of inclusion, most 
administrative data derived from the medical files were outdated, because many 
patients had not visited their dermatologists recently. This procedure included record 
linkages to the digital information systems of the participating hospitals, an electronic 
telephone record database and the Municipal Personal Record Database (MPRD). 
Additionally, municipalities and the Central Bureau of Genealogy were consulted. By 
the end of these procedures, addresses and vital status of 88% of the patients was 
updated (12,272/14,009). A total of 2,656 patients (19%) had deceased and 229 
patients had emigrated. In case a patient had deceased, efforts were made to retrieve 
current information of the partner, whom we considered as a potential proxy. This 
resulted in the identification of 604 partners of deceased patients (23.3%), but only 
412 (68%) were still alive and could be invited for the study.
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diagnosis of cancer, date of death, date of loss to follow-up or December 31, 2003, 
whichever came first. Separate analyses were conducted on specific outcomes: 1) 
overall cancer (total of all the tumours) 2) skin cancer (excluding basal cell carcinoma) 
3) non-skin cancer and 4) different (groups of) tumour sites. If a patient was diagnosed 
with multiple tumours, only the first tumour was included in the analyses on overall 
cancer. 
 Coal tar exposure was divided into two categories: a reference/control category 
(‘non-exposure’ category) of patients treated with dermatocorticosteroids only 
(assumed to carry no increased risk of cancer) and an exposure category of patients 
treated with coal tar (including PL and/or LCD). As pix lithantracis contains far more 
carcinogenic PAH than LCD, the analyses were also performed with coal tar exposure 
divided into three categories: reference (similar to above), ‘high exposure’ including 
patients treated with pix lithantracis (regardless of exposure to LCD) and ‘low 
exposure’ including patients treated with LCD only. Patients in the exposure categories 
could also have been treated with other therapies (e.g. ointments, photo(chemo)
therapy or systemic therapies). 
 In all final models, the risk of coal tar was adjusted for age (continuous), gender, 
severity of skin disease (more than 10% body area affected vs less than 10%), an 
interaction term of coal tar and severity, calendar period of diagnosis (1960-69, 
1970-79, 1980-89), PUVA (yes vs no), systemic therapy (yes vs no) and smoking 
(current smoking and ever smoked vs never smoked). We chose the moment at 
which the skin disease was most extensive to assess the maximum severity of the 
skin disease. We did not use any information on fluctuations of severity in the 
analyses. The models were not adjusted for skin type, history of sun exposure or 
alcohol consumption, because these variables did not alter the risk estimates of the 
treatment effects in the proportional hazards models.
 Data on smoking habits were only available from the patients with a completed 
questionnaire and were consequently missing in a large proportion of the cohort 
(58%). To handle these missing data, a multiple imputation technique (MI) was 
used.18-20 The proportionality assumption of each variable was checked by visual 
inspection of log-log survival plots and by examining the effect of adding a 
time-dependent interaction term. Analyses were performed with SAS, version 8.2 
(SAS Institute, Cary, NC).
Results
Characteristics of the cohort (Table 1)
809 patients in the total cohort of 14,009 patients were excluded from the analyses, 
because of missing or invalid data on key variables, such as diagnosis of psoriasis or Fi
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Table 1   Characteristics of patients in the total cohort and stratified by psoriasis 
and eczema.
Characteristic Total cohort 
(13,200)
Psoriasis  
(4,315)
Eczema  
(8,885)
Gender (male/female %) 47/53 52/48 45/55
Median age at diagnosis (range) 28.4 yr (0 - 95.7) 31.1 yr (0 - 95.7) 27.2 (0 - 91.4)
Calender period of diagnosis
   1960-1969 (%) 2476 (18.8) 931 (21.6) 1545 (17.4)
   1970-1979 (%) 4160 (31.5) 1575 (36.5) 2585 (29.1)
   1980-1989 (%) 6564 (49.7) 1809 (41.9) 4755 (53.3)
Status at end of follow-up
   Diagnosed with cancer (%) 1048 (7.9) 421 (9.8) 627 (7.1)
   Deceased without cancer (%) 1951 (14.8) 725 (16.8) 1226 (13.8)
    Censured at December,  
31, 2003 (%)
9346 (70.8) 2840 (65.8) 6506 (73.2)
   Lost to follow-up (%) 855 (6.5) 329 (7.6) 526 (5.9)
Median duration follow-up (yr) 21 22.5 20.5
   1 - 9 yr (%) 1433 (10.9) 502 (11.6) 928 (10.5)
   10 - 19 yr (%) 4634 (35.1) 1219 (28.3) 3414 (38.4)
   20 - 29 yr (%) 4415 (33.4) 1528 (35.4) 2856 (32.5)
   >30 yr (%) 2718 (20.6) 1063 (24.6) 1654 (18.6)
Severity of skin disease  
(% area affected)
   <1% 2759 (20.9) 375 (8.7) 2381 (26.8)
   2-9% 4528 (34.3) 1290 (29.9) 3234 (36.4)
   10-30% 3907 (29.6) 1696 (39.3) 2221 (25.0)
   >30% 2006 (15.2) 954 (22.1) 1049 (11.8)
Use of coal tar ointments (%)
   Never1 5138 (38.9) 1234 (28.6) 3904 (43.9)
    Only liquor carbonis detergens, 
no pix lithantracis1
4927 (37.3) 2256 (52.3) 2671 (30.1)
    Pix lithantracis with/without liquor 
carbonis   detergens1
3135 (23.8) 825 (19.1) 2310 (26.0)
Table 1   Continued.
Characteristic Total cohort 
(13,200)
Psoriasis  
(4,315)
Eczema  
(8,885)
Use of other therapies (%)
  Topical
    Local corticosteroids 96.6 96.6 96.5
    Vitamin D3 analogues 11.5 32.4 -
    Topical calcineur-inhibitors 1.9 1.0 2.4
    Dithranol 3.4 10.2 -
  Systemic
    Methotrexate 5.2 14.9 0.5
    Retinoids 4.9 13.2 -
    Cyclosporin 1.7 3.5 0.8
    Fumarates 1.8 5.1 -
    Oral prednison 9.6 5.1 11.8
  Photo(chemo)therapie
    PUVA 13.1 27.2 6.2
    UVB 16.7 33.5 8.6
    Goeckerman 3.5 9 0.9
Smoking status (%)2
   Never 1499 (11.4) 400 (9.3) 1099 (12.4)
   Former 2489 (18.9) 997 (23.1) 1492 (16.8)
   Current 1526 (11.5) 559 (13.0) 967 (10.7)
   Unknown 16 (0.1) 6 (0.1) 10 (0.1)
    Missing  
(no data from questionnaire)
7670 (58.1) 2353 (54.5) 5317 (59.8)
Alcohol (%)2
   <1 days/week 2561 (19.4) 859 (19.9) 1702 (19.2)
   1-2 days/week 1062 (8.0) 383 (8.9) 679 (7.6)
   3-5 days/week 824 (6.3) 296 (6.9) 528 (5.9)
   >5 days/week 973 (7.4) 373 (8.6) 600 (6.8)
   Unknown 110 (0.8) 51 (1.2) 59 (0.7)
    Missing  
(no data from questionnaire)
7670 (58.1) 2353 (54.5) 5317 (59.8)
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4eczema or date of diagnosis. One-third of the cohort consists of patients with 
psoriasis and two-thirds with eczema. Over 60% of the patients with psoriasis had a 
severe form, i.e., more than 10% of their body was affected. In eczema, this applied 
to less than 50%. In the total cohort, 61% of the patients had been treated with coal 
tar: approximately 60% with liquor carbonis detergens and 40% with pix lithantracis. 
Many other therapies had also been applied to these patients. Systemic therapies 
and photo(chemo)therapy had been applied to 25% and 46% of the patients with 
psoriasis, respectively. These percentages were much lower in the patients with 
eczema. 
 Valid information on duration of coal tar therapy could be obtained from 
approximately 1,100 patients only. This made a robust dose-response evaluation of 
coal tar exposure and the risk of cancer impossible. The available information showed 
a median use of pix lithantracis of 4 months (range: 1-300 months) and the median 
use of liquor carbonis detergens was 6 months (range: 1-500 months). 
Risk of cancer after coal tar treatment 
The median duration of follow-up was 21 years. During follow-up, 1,327 tumours had 
been diagnosed (Table 2). Table 3 presents the results of the multivariable proportional 
hazards regression analyses on the relative risk of cancer after coal tar treatment. No 
increased risk of skin cancer and non-skin cancer was found after coal tar treatment 
Table 1   Continued.
Characteristic Total cohort 
(13,200)
Psoriasis  
(4,315)
Eczema  
(8,885)
Skin type (%)2
   Type 1 (always burns, never tans) 426 (3.3) 167 (3.9) 259 (2.9)
    Type 2 (burns easily, tans 
minimally)
1764 (13.3) 555 (12.9) 1209 (13.6)
    Type 3 (burns moderately, tans to 
light brown
2688 (20.4) 977 (22.6) 1711 (19.3)
   Type 4 (burns minimally, tans well) 564 (4.3) 226 (5.2) 338 (3.8)
   Unknown 88 (0.6) 37 (0.9) 51 (0.6)
    Missing  
(no data from questionnaire)
7670 (58.1) 2353 (54.5) 5317 (59.8)
Abbreviations: PVA, psoraleen plus UVA.
1  Patients in all three categories could also have been treated with other therapies.
2   Percentages are based on the part of the cohort that returned the questionnaire (5,530, 1,962 and 3,568 
in the total cohort and in patients with psoriasis and with eczema, respectively).
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(HR = 1.09; 95% CI = 0.69-1.72 and HR = 0.92; 95% CI = 0.78-1.09, respectively). 
The risk of haematological malignancies seemed to be slightly decreased, especially 
in psoriasis, but these analyses only included a small number of tumours. In the 
patients with eczema, the risk of gastrointestinal cancer after coal tar treatment was 
approximately 50% lower than that in the patients treated with dermatocorticosteroids 
alone (HR = 0.57; 95% CI = 0.37-0.89). Opposite results were observed regarding 
the risk of bladder and urinary tract cancer in patients with eczema (HR = 1.83; 95% 
CI = 0.73-4.58) compared to patients with psoriasis (HR = 0.51; 95% CI = 0.14-1.92). 
However, these results were based on small numbers (30 and 21, respectively) and 
were not statistically significant.
Table 4 presents the results of the multivariable analyses on the high (pix lithantracis) 
and low (liquor carbonis detergens) coal tar exposure categories. Neither of the coal 
tar categories showed an increased risk of non-skin cancer. The hazard ratio of skin 
cancer for pix lithantracis in patients with psoriasis or eczema was 0.66 (95% CI = 
0.33-1.30), whereas it was 1.28 (95% CI = 0.80-2.06) for liquor carbonis detergens. 
Comparable results were found in the psoriasis group: HRs for liquor carbonis 
detergens and pix lithantracis were 1.35 (95%CI = 0.53-3.44) and 0.33 (95%CI = 
0.07-1.69), respectively. Similar risk estimates of gastrointestinal cancer were 
observed in patients with psoriasis and eczema in both the low and high exposure 
group. In patients with eczema, the risk of gastrointestinal cancer after liquor carbonis 
detergens was almost 50% lower compared with the reference group (HR = 0.54; 
95% CI = 0.33-0.89). In patients with psoriasis or eczema the risk of cancer of the 
female reproductive organs after pix lithantracis was increased (HR = 1.26; 95% CI = 
0.61-2.58). This was caused by a three-fold increased risk of tumours of the female 
reproductive organs in patients with eczema (HR = 2.89; 95% CI = 1.30-6.43). 
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Discussion 
The main conclusion of this study is that, overall, the use of coal tar ointments is not 
associated with an increased risk of cancer. With regard to the risk of skin cancer 
after coal tar exposure, separate analyses of pix lithantracis and liquor carbonis 
detergens showed unexpected results: a higher risk of skin cancer in the “low” coal 
tar exposure group than in the “high” exposure group (HR = 1.28 vs HR = 0.66). 
However, these results were not statistically significant. The intensity of PAH exposure 
is not only determined by the PAH concentration, but also by the duration of exposure. 
The use of pix lithantracis is restricted to a hospital or day-care setting, because of 
staining of furniture and clothes and the strong odor. In contrast, liquor carbonis 
detergens can be used at home and therefore, most patients use these ointments for 
a longer period of time. Patients treated with pix lithantracis were probably exposed 
to a high concentration of PAH over a short period, whereas patients treated with 
liquor carbonis detergens were exposed to a lower dose of PAH over a longer period. 
Occupational studies have shown that the risk of non-melanoma skin cancer was 
increased after chronic exposure to low doses of PAH.3;5-7  
 Therefore, it seems possible that tissue (skin) is capable to repair any damage 
after short-term exposure to PAH, but may not always be capable of doing so during 
long-term exposure. 
 Most of the studies that investigated the risk of skin cancer after coal tar treatment 
did not find an increased risk of non-melanoma skin cancer8-12. Only Stern et al. 
reported an increased risk of non-melanoma skin cancer in patients with psoriasis.13 
However, these patients were drawn from the PUVA cohort and all had therefore 
received this carcinogenic therapy.
Very few studies have analyzed the risk of internal malignancies after coal tar 
treatment. A fairly small study by Jones et al. (1985) evaluated the risk of internal 
malignancies in 719 patients with psoriasis.9 These patients had received coal tar 
therapy intermittently over a 10-year period and had never been exposed to UVB, 
PUVA or cytotoxic therapies. The results indicated that coal tar treatment did not 
increase the risk of internal tumours. Hannuksela-Svahn et al. (2000) conducted a 
large cohort study to estimate the risk of cancer in 5,687 hospitalized patients with 
psoriasis.8 A nested case-control study within this cohort study showed a non-signif-
icant increase in the risk of non-Hodgkin’s lymphoma after treatment with the 
Goeckerman regimen (OR=1.2; 95% CI: 0.1-16.8).
In the tumour-specific analyses, we found a decreased risk of gastrointestinal cancer. 
This decreased risk seemed to be driven by a decreased risk of colon cancer (HR = 
0.57; 95% CI = 0.32-1.03). Although we did not expect the gastrointestinal tract to be T
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Besides coal tar, many other therapies have been applied in the treatment of psoriasis 
and eczema. Most of these therapies have mild-to-moderate or even severe 
side-effects. The use of topical calcineurin inhibitors in eczema has been increasing 
since their introduction. These agents modify the immune regulatory functions of the 
skin and may therefore increase the risk of skin cancer.21;22 Until now, epidemiological 
studies have not shown any increased risk of (skin) cancer after the use of calcineurin 
inhibitors, but only short-term follow-up data are available.22 If patients have severe 
skin diseases or do not respond to topical treatment, systemic therapies or 
photo(chemo)therapies can be applied. Most of these modalities have moderate-to-
severe carcinogenic (PUVA and cyclosporine), hepatotoxic (methotrexate, retinoids) 
or teratogenic (retinoids) side effects.23-25
 The risk of skin cancer after PUVA has been extensively studied and most studies 
showed an increased risk of skin cancer  8;26-28. Several studies showed that patients 
exposed to long-term treatment with cyclosporine after an organ transplant have a 
significantly increased risk of non-melanoma skin cancer.29-33 Some of the studies 
that analyzed the risk of skin cancer after cyclosporine in psoriasis also showed an 
increased risk of skin cancer.34-36 Since their introduction a few years ago, the use of 
biologicals (e.g. infliximab, etanercept and adalimumab) has been rapidly increasing 
in the treatment of psoriasis. These biologicals suppress specific parts of the immune 
system, and hece in theory, they may come along with an increased risk of cancer. 
Cost-effectiveness and cost-utility studies comparing traditional and new modalities 
are not yet available.37;38 
This large study with long time follow-up showed no increased risk of cancer after 
coal tar therapy in patients with psoriasis or eczema. Coal tar exposure was rather 
short in our cohort, but this may reflect dermatological coal tar exposure in practice. 
We conclude that our study showed no reasons for safety concerns with respect to 
the risk of cancer after the use of coal tar in patients with psoriasis and eczema. It is 
therefore ungrounded to consider coal tar as obsolete because of its alleged 
carcinogenic action.
a tumour risk site after coal tar treatment (in contrast with the bladder, lymphatic and 
haematological system), a decreased risk was unexpected and we cannot think of a 
logical explanation. The study by Jones et al. reported an increased risk of colon 
cancer in men, but not in women. However, these results were based on very small 
numbers of tumours (n=6).9 
 Another remarkable finding in our study was the difference in the risk of bladder 
and urinary tract cancer between patients with psoriasis (HR = 0.51; 95% CI = 
0.14-1.92) and with eczema (HR = 1.83; 95% CI = 0.73-4.58). However, the numbers 
of tumours were fairly small and therefore this finding may be due to chance. 
This is the first cohort study with sufficient numbers of patients and follow-up for 
assessing the overall risk of cancer after limited coal tar treatment in a valid way. In 
addition, data on possible risk factors for cancer, such as age, smoking and non-coal 
tar therapies were collected that made it possible to adjust all estimates for these risk 
factors. 
 Unfortunately, we were unable to estimate a dose-response relation of coal tar 
exposure and the risk of cancer. It was impossible to derive reliable information on the 
exact duration of coal tar treatment from the medical files. Only a limited proportion 
of the patients (treated with coal tar) returned the questionnaire and answered the 
questions on the duration of coal tar therapy (approximately 1,100 patients). The 
number of cases was therefore too small to reliable estimate the risk of cancer after 
different levels of coal tar exposure. The information on duration of exposure showed 
that patients were treated with coal tar for a relatively short period of time. This is 
consistent with our experience from daily practice in which pix lithantracis is mainly 
used during hospitalization or in day-care clinic. The duration of treatment with liquor 
carbonis detergens is somewhat longer, but still limited and frequently alternated with 
other topical therapies. We therefore believe that our data reflect the duration of coal 
tar use in dermatological practice.
No distinction could be made between the risk of melanoma and squamous cell skin 
carcinoma, because we did not make this subdivision in the questionnaire. Although 
we received type-specific cancer incidence data from the Netherlands Cancer 
Registry (and Statistics Netherlands), we could not make this subdivision of skin 
cancer in our final analyses, because we also used data on cancer occurrence from 
the questionnaires. Basal cell carcinomas are not registered in the Netherlands 
Cancer Registry. Consequently, we could not include this type of skin cancer in our 
analyses. Occupational studies on PAH exposure showed an increased risk of 
squamous cell carcinomas, and hence this type of skin cancer may be more related 
to PAH exposure than BCC. 2-7
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Introduction
Coal tar is an effective therapy in the treatment of chronic skin diseases, such as 
psoriasis and eczema.1 It contains more than 10,000 compounds, including polycyclic 
aromatic hydrocarbons (PAHs) in high concentrations. Some PAH, such as benzo(a)
pyrene are classified as human carcinogens.2;3 Because of the carcinogenic potency 
of PAHs, concerns have been raised about the risk of cancer after coal tar treatment in 
patients with skin diseases. The skin is an important route of uptake after dermatological 
exposure to coal tar.4 Several studies have therefore investigated the risk of skin cancer 
after coal tar treatment but most studies5-8, except one of Stern and colleagues9, did not 
observe an increased risk. After application, coal tar is absorbed and metabolized in 
the skin and body. After metabolisation, several metabolites of PAHs are excreted in the 
urine.10 Therefore, dermatological use of coal tar might be associated with an increased 
risk of non-skin cancer, especially bladder cancer. The risk of non-skin cancer in 
patients treated with coal tar was investigated in only a few studies and most of these 
studies did not observed an increased risk of internal malignancies.6;11-13 However, none 
of the previously performed studies was specifically aimed at the association between 
bladder cancer and dermatological application of coal tar preparations. In this 
case-control study we examined the risk of bladder cancer after exposure to coal tar 
ointments used in the dermatological practice.
Patients and methods
Study population and data collection
Patients were identified by the Department of Registry and Research of the 
Comprehensive Cancer Centre The Netherlands, location Nijmegen. All bladder 
cancer patients diagnosed between 1995 and 2006 under the age of 75 in this region 
and alive at time of data collection were invited to participate in a study on genetic 
susceptibility for bladder cancer.14 Patients filled out a detailed postal questionnaire 
concerning topics such as demographic factors, life style, history of diseases (e.g. 
cancer) and medication use. The response rate was 62%. For the current study, only 
bladder cancer cases with urothelial cell carcinoma were included (n=1,501). Patients 
with missing data on skin disease, smoking status or use of coal tar ointments were 
excluded (n=114). A total of 1,387 cases were included in the analyses. 
Controls were obtained through the Nijmegen Biomedical Study (NBS), a population-
based survey conducted by the Radboud University Medical Centre in 2002.15 A 
random selection of inhabitants of Nijmegen were invited to participate in a study on 
risk factors for (any) disease by filling out a detailed postal questionnaire. In 2008, an 
Abstract
Background
Coal tar ointments are used as treatment of various skin diseases, especially psoriasis 
and eczema. These ointments contain several carcinogenic polycyclic aromatic 
hydrocarbons (PAHs). Metabolites of these PAHs are excreted in the urine and 
therefore, dermatological use of coal tar may be associated with an increased risk of 
bladder cancer. 
Objective
To study the association between dermatological use of coal tar ointments and 
bladder cancer.
Methods 
A population-based case-control study was conducted including 1,387 cases 
diagnosed with bladder cancer and 5,182 population controls. Information on the use 
of coal tar, history of skin disease and known risk factors for bladder cancer was 
obtained through postal questionnaires. Logistic regression analyses were performed 
to estimate the risk of bladder cancer after coal tar treatment, adjusted for age, 
gender, smoking status, duration of smoking and intensity of smoking. 
Results
The use of coal tar ointments was approximately equal among cases and controls 
(3.8% versus 3.0%, respectively). Dermatological application of coal tar was not 
significantly associated with bladder cancer (adjusted OR = 1.37; 95% CI: 0.93-2.01). 
An inverse association between bladder cancer and a history of skin disease was 
observed (adjusted OR = 0.74; 95% CI: 0.61-0.90).
Conclusion
This is the first study that was specifically aimed to study the association between the 
use of coal tar preparations and bladder cancer. The results suggest that there is no 
reason for safety concerns with respect to the risk of bladder cancer after the use of 
coal tar preparations in dermatological practice. 
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 The risk of bladder cancer associated with exposure to coal tar ointments is 
presented in Table 2. The use of coal tar was not significantly associated with bladder 
cancer (OR=1.37; 95% CI = 0.93-2.01). The risk of bladder cancer was comparable 
in men and women. The OR in the subgroup of non-smokers was comparable to the 
total group (OR=1.20 versus OR=1.37), but this result was based on small numbers 
(n=4  non-smoking cases). 
additional questionnaire, more specifically aimed at potential risk factors for bladder 
cancer was sent to all participants of the NBS who gave consent for further research 
and were still alive at that point in time. A total of 5,613 (64%) persons returned this 
second questionnaire. Persons who were diagnosed with cancer (except for basal 
cell carcinomas of the skin) at the time of data collection were excluded (n=303), as 
well as controls with missing data on smoking status and skin disease (n=128). Coal 
tar exposure was measured as “yes” versus “no”. People with missing data on this 
variable (n=1,481) were included in this category as well (assuming that persons who 
did not answer yes to this question, did not use these preparations). A total of 5,182 
controls were included in the analyses. All patients and controls gave written informed 
consent. The study was approved by the Institutional Review Board of the Radboud 
University Medical Centre.
Statistical analysis 
Descriptive analyses were performed to provide insight in the characteristics of the 
patients and controls. Logistic regression analyses were performed to estimate Odds 
Ratios (OR) and 95% Confidence Intervals (95% CI) for the association between the 
use of coal tar ointments and bladder cancer. These analyses were adjusted for age 
at completing the questionnaire, gender and smoking. Smoking and male status are 
strong risk factors for bladder cancer. To exclude the effect of smoking in the 
association between coal tar and bladder cancer, subanalyses in non-smokers were 
performed. In addition, subanalyses in men and women were performed. We also 
analyzed the association between occurrence of skin disease and bladder cancer, 
because coal tar ointments are applied in patients with skin diseases. All models 
were not adjusted for height, weight, use of temporary and/or permanent hair dyes 
and educational level, because these variables did not alter the effect estimates in 
the models. All statistical analyses were performed in SAS (SAS system for Windows, 
version 9.2, SAS institute, Cary, NC).
Results
This study included 1,387 patients and 5,182 controls (Table 1). Patients were older at 
the time of completing the questionnaire compared to controls (67 yr versus 57 yr). 
Smoking, both current and former, was more frequent in patients. Among current and 
former smokers, patients had smoked for a longer period of time and the intensity of 
smoking was higher. Education level among patients was lower compared to controls. 
The use of coal tar ointments was approximately equal in both groups (3.8% versus 
3.0%). Among individuals exposed to coal tar, skin diseases were more prevalent 
compared to the individuals not-exposed (94% versus 16.4%) (data not shown).
Table 1   Characteristics of the study population.
 Cases  
(n = 1,387)
Controls  
(n = 5,182)
Age at completing the questionnaire (y) 1 67.3 ± 9.4 57 ± 16
Gender (% men) 84 46
Smoking status
Never smokers (%) 10.7 36.2 
Former smokers (%) 64.9 47.6 
  Number of cigarettes (cig/day) 1 15.4 ± 4.5 12.6 ± 8.7
  Smoking duration (y) 1 29.2 ± 13.7 20.4 ± 13.6
  Age at start smoking (y) 1 17.5 ± 4.5 17.7 ± 4.6
Current smokers (%) 24.4 16.2
  Number of cigarettes (cig/day) 1 15.3 ± 5.1 13.7 ± 8.1
  Smoking duration (y) 1 42.7 ± 13.1 32.1 ± 15.2
  Age at start smoking (y) 1 17.6 ± 5.1 17.4 ± 5.0
Educational level (%)
  Primary school 15.9 7.2
  Technical/professional school 52 53.1
  Secondary school 22.3 21.9
  University degree 9.8 17.8
Use of temporary and/or permanent dyes (%) 13.9 44.9 
Skin disease (%) 14.4 18.8 
Use of coal tar ointments (%) 3.8 3.0 
1  Mean ± SD
Abbreviations: (y): years; (cig/day): cigarettes/day
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We also investigated the association between bladder cancer and skin diseases. An 
inverse association between the occurrence of skin disease and bladder cancer was 
observed, although restricted to men. It is difficult to explain this observed association, 
because no information on the type of skin disease was available from the 
questionnaires. However, it can be assumed that a major part of the reported skin 
diseases will be eczema and psoriasis. In both skin diseases, a hyperreactive immune 
system leads to chronic inflammation. This chronic stimulation of cells of the immune 
system may lead to randomly occurring pro-oncogenic mutations in actively dividing 
cells and therefore, to an increased risk of cancer. Also, patients with severe psoriasis 
or eczema are often treated with potential carcinogenic therapies, such as PUVA and 
cyclosporine. Several studies have evaluated the risk of bladder cancer in patients 
with psoriasis or eczema, but showed conflicting results.5;6;18-20 Several patients in 
these studies had been treated with carcinogenic therapies and as a result, it is not 
possible to exclude the effect of these therapies on the risk of cancer. In future 
research it is worthwhile to only include patients with one type of skin disease to study 
the association between skin disease and bladder cancer.
Information was assessed after the diagnosis of bladder cancer and therefore, recall 
bias cannot be excluded. We assume that recall is limited, because questions on 
these topics were part of a questionnaire with a wide spectrum of questions and we 
have no reason to assume that patients or controls associate the use of coal tar or 
occurrence of skin disease with the development of bladder cancer. No information 
on the type and duration of coal tar preparations was asked in the questionnaires. In 
dermatological practice pix lithantracis and liquor carbonis detergens are used. Pix 
lithantracis contains far more PAHs than liquor carbonis detergens. In our earlier 
performed cohort study no differences in cancer risk was observed between the use 
of pix lithantracis and liquor carbonis detergens.13 In the present study it was not 
possible to confirm these results because no information on the type of coal tar 
preparations was collected. 
We conclude that there is no reason for safety concerns with respect to the risk of 
bladder cancer after the use of coal tar preparations in dermatological practice. 
 An inverse association between skin disease and bladder cancer was observed 
(OR=0.74; 95% CI=0.61-0.90) (Table 2), although this inverse association was 
restricted to men (OR men=0.68; 0.54-0.85; OR women=1.05; 95% CI 0.70-1.58). 
Discussion
This is the first population-based case-control study specifically aimed at assessing 
the risk of bladder cancer after dermatological use of coal tar. No association 
between dermatological exposure to coal tar and bladder cancer was observed. 
Several studies have shown that occupational exposure to polycyclic aromatic 
hydrocarbons is associated with an increased risk of bladder cancer.2;3;16 The 
increased bladder cancer risk in occupational studies was observed in workers with 
prolonged occupational exposure, whereas dermatological use of coal tar is most 
often limited to a much shorter duration of exposure.10;17 The results from the present 
case-control study are in accordance with the results found in some other studies, 
although these studies did not specifically address the risk of bladder cancer.6;11-13 
Differences in cancer risks between occupational studies and studies in patients may 
be explained by the duration of PAH exposure. Possibly, the body is capable of 
repairing tissue damage, following short-term exposure to PAH, but not to the same 
extent after long-term exposure.
Table 2   Risk of bladder cancer associated with use of coal tar ointments and 
occurrence of skin disease.
 Coal tar Skin disease
 OR (95% CI) OR (95% CI)
All1 1.37 (0.93-2.01) 0.74 (0.61-0.90)
Gender2
   Male 1.32 (0.85-2.05) 0.68 (0.54-0.85)
   Female 1.57 (0.72-3.39) 1.05 (0.70-1.58)
Never smokers3 1.20 (0.41-3.53) 1.08 (0.68-1.72)
1   OR were adjusted for age at completing the questionnaire, gender, smoking status, duration of smoking 
(in years) and intensity of smoking (cigarettes/day).
2   OR were adjusted for age at completing the questionnaire, smoking status, duration of smoking (in years) 
and intensity of smoking (cigarettes/day).
3   OR were adjusted for age at completing the questionnaire and gender.
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Introduction
Psoriasis and eczema are common, inflammatory skin diseases. In both skin 
diseases, a hyperreactive immune system leads to chronic inflammation. The 
pathogenesis of psoriasis is complex and not completely understood. Psoriasis is 
conceptualized as an auto-immune disease caused by interactions between immune 
cells and keratinocytes, proinflammatory cytokines and chemical mediators.1;2 
Because of the hyperreactive immune status, psoriasis patients may have an 
increased risk of lymphoproliferative malignancies. Some studies reported an 
increased risk of lymphomas 3-6, while other studies did not show an increased risk.7-9 
Psoriasis is characterized by an increased turnover of keratinocytes and, as a 
consequence, an increased proliferation of cells, which may predispose for the 
development of skin cancer.7 Most studies reported an increased risk of non-melanoma 
skin cancer in psoriasis patients.5-10 Also, increased risks of several non-skin cancers, 
including larynx, pharynx, lung, pancreas and breast cancer have been reported, 
although these results are not consistent.5-10 
Atopic eczema can be regarded as an inflammatory skin disease, linked to an altered 
T-lymphocyte response with an initial shift toward the Th2 response and altered 
regulatory T-cells, which leads to increased cytokine production of interleukin (IL)-4, 
IL-5 and IL-13.11 It has been hypothesized that this hyperreactive state may lead to 
increased tumour immunosurveillance, which may decrease the probability of 
proliferation of aberrant cells and therefore, decreases the probability to develop 
malignancies.12;13 On the other hand, atopic eczema causes chronic stimulation of 
cells of the immune system that may lead to randomly occurring pro-oncogenic 
mutations in actively dividing cells and therefore, to an increased risk of cancer. This 
is postulated in the antigenic stimulation hypothesis.13;14 Several studies investigated 
the risk of cancer in patients with atopic eczema. Two cohort studies in hospitalized 
eczema patients found an increased risk of overall cancer.15;16  Most studies reported 
inverse associations between atopic disease (including atopic eczema) and the risk 
of glioma.13;17 Also, a fairly consistent protective effect of atopic disease for childhood 
leukemia and adult pancreatic cancer is described in several studies.13 Concerning 
other tumours, like breast, lymphoma, colorectal and lung tumours, studies showed 
inconsistent results.14-16;18-21 Differences in study design and assessment of atopy 
(self-reported, medical files or specific IgE measurement) may cause variability in 
results which complicates comparisons of study results. 
In all reported studies of cancer risk in patients with psoriasis or eczema, patients 
have been treated with several therapies. Most of these studies included hospitalized 
patients and therefore it can be assumed that these patients have been treated with 
Abstract
Background 
Psoriasis and eczema are common skin diseases that often require long-term 
treatment. Several studies showed an increased risk of cancer, but in these studies it 
was not possible to disentangle the effects of treatment and the underlying skin 
disease on the risk of cancer. 
Objectives 
To assess the risk of cancer in patients with psoriasis or eczema, independent of 
treatment.
Methods 
A cohort study was performed including 13,200 patients diagnosed between 1960 
and 1990 with psoriasis or eczema in the Netherlands. Standardized incidence ratios 
(SIRs) were calculated using gender-, age and calendar year specific cancer 
incidence rates. To exclude the effect of treatment, sub-analyses were performed in 
patients treated with dermatocorticosteroids only. 
Results 
The overall risk of cancer was slightly increased in both psoriasis (SIR= 1.07; 
95%CI=0.98-1.16) and eczema (SIR=1.09; 95%CI=1.01-1.16). The risk of cancer in 
the subgroup of patients treated with dermatocorticosteroids only (i.e. treatment-in-
dependent risk of cancer) was borderline increased in psoriasis patients (SIR=1.20; 
95%CI=0.95-1.48), as well as in patients with eczema (SIR=1.10; 95%CI=0.98-1.22). 
A non-statistically significant increased risk of lymphomas was observed in untreated 
patients with psoriasis (SIR=2.66; 95%CI=0.86-6.21) and eczema (SIR=1.67; 
95%CI=0.93-2.77). 
Conclusion 
Our results suggest that patients with psoriasis or eczema have a slightly increased 
risk of cancer, independent of therapy. A possible explanation may be the chronic 
stimulation of cells of the immune system due to the chronic state of inflammation in 
these skin diseases. 
92 93
Risk of cancer risk in a cohort of patients with psoriasis or eczema Chapter 5.1
5
Cancer occurrence
Occurrence of cancer was assessed through information from the medical files and 
questionnaires. In addition, the cohort was linked to the Netherlands Cancer Registry 
(NCR). The NCR has nation-wide coverage since 1989 and at time of linkage, cancer 
incidence data were complete until 2003. Record linkage was performed for all living 
and deceased patients, except for those patients who explicitly refused linkage to 
population and health registries (n=406). Although non-responders and deceased 
patients did not give explicit permission, linkage to the NCR is allowed using a strict 
privacy protocol.23 In order to assess cancer occurrence among patients deceased 
before 1989, record linkage to the Causes of Death Registry of Statistics Netherlands 
was performed. In case a malignancy was reported as underlying cause of death, 
cancer site and date of death were used as proxies for cancer occurrence and date 
of diagnosis. In case the information retrieved from the NCR did not correspond with 
the already available information from the questionnaires and the medical files, the 
information from the NCR was assumed to be superior.
Statistical analyses
Standardized incidence ratios (SIR) were calculated to assess the risk of (site-
specific) cancer. The SIR is the ratio of the observed and the expected number of 
cases of cancer.24 In order to obtain the expected numbers, the national incidence 
rates stratified by sex, 5-year age group and calendar year for each cancer type were 
used. These incidence rates were obtained from the NCR for the period 1989-2003. 
As the NCR was not complete until 1989, cancer incidence rates from the 
Comprehensive Cancer Centre South were used as proxies for the national incidence 
rates for the period 1975-1989. The number of person-years at risk was defined as the 
time between date of diagnosis of the skin disease until date of diagnosis of cancer, 
date of death, last date of follow-up or December 31, 2003, whichever came first. No 
information on cancer occurrence before 1989 (start nation-wide coverage NCR) was 
available for patients who did not return a questionnaire and were not deceased (i.e. 
censured at December 31, 2003). For these patients (n= 4,240) the number of 
person-years were calculated from January 1, 1989 until December 31, 2003.  In case 
a patient developed multiple tumours at different sites, only the first tumour was 
included in the calculations concerning total cancers, but the different tumours were 
included in the cancer site-specific calculations. In case of multiple tumours at the 
same site, only the first tumour was included in site-specific calculations. Basal cell 
carcinomas (bcc) are not registered in the NCR and therefore not included in the 
analyses. 
SIRs were calculated for the total cohort of patients, stratified by skin disease. To 
exclude the effect of treatment on the risk of cancer, SIRs were calculated in a 
potential carcinogenic therapies, such as coal tar, PUVA or cyclosporine. As a result, 
it is not possible to exclude the effect of treatments on the risk of cancer.
In this cohort study the risk of cancer in patients with psoriasis or eczema was 
investigated by comparing the number of observed cancer diagnoses in the cohort 
to the expected number of cancer diagnoses based on cancer rates from the general 
population. To assess the treatment-independent risk of cancer we selected patients 
treated with dermatocorticosteroids only. Furthermore, to evaluate the risk of cancer 
in patients treated with potential carcinogenic therapies, we performed analyses in 
subgroups of patients treated with coal tar, PUVA and systemic therapies.
Materials and methods
This study is part of a large historical cohort study, the LATER study (Late effects of 
coal tar treatment in eczema and psoriasis; the Radboud study). This study was 
initiated in 2003 and designed to assess the risk of cancer after coal tar treatment in 
patients with psoriasis or eczema.22 Between January 2004 and June 2006, over 
300,000 medical records stored in the archives of the Departments of Dermatology 
of two university hospitals and one large teaching hospital were searched manually 
to identify eligible patients. A total of 14,009 patients fulfilled the inclusion criteria. 
Administrative data and information concerning the medical history, like date of 
diagnosis, date of last visit to the dermatologist, severity of skin disease, therapies, 
history of cancer and vital status were retrieved from the medical files. Because data 
on cancer, especially non-skin cancer, was not systematically recorded in the 
dermatology files, this incomplete information was supplemented by questionnaires 
and record linkage to the Netherlands Cancer Registry and Causes of Death Registry 
(described in section cancer occurrence). At time of inclusion, most administrative 
data from the medical files were outdated and therefore an update of addresses and 
vital status was necessary before questionnaires could be sent. A labour-intensive 
stepwise procedure was performed to update addresses and vital status. Detailed 
information on this procedure and the data collection by questionnaires has been 
described previously.22 Data from the questionnaires were added to the data already 
collected from the medical files. A total of 5,927 questionnaires were returned, 
corresponding with a response rate of 61%. 809 patients of the cohort of 14,009 
patients were excluded from the analyses, because of missing or invalid data on 
critical variables like diagnosis of psoriasis or eczema or date of diagnosis. The 
LATER study was approved by the Institutional Review Boards of all three participating 
hospitals. 
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subgroup of patients who were treated with dermatocorticosteroids only. These SIRs 
represent the treatment-independent risk of cancer. Finally, sub-analyses were 
conducted in patients treated with coal tar, PUVA and systemic therapies. 95% 
Confidence Intervals (CI) were calculated assuming a Poisson distribution of the 
number of observed cases.25 All the analyses were performed with SAS, version 8.2 
(SAS Institute, Cary, NC).
Results
The characteristics of the patients are shown in Table 1. One third of the cohort 
consists of patients with psoriasis and two thirds of patients with eczema. Patients 
with psoriasis had more severe skin disease compared to patients with eczema, i.e. 
62% of the psoriasis patients had more than 10% of their body affected, compared to 
37% of patients with eczema. This difference in severity of skin disease was also 
reflected by the use of systemic therapies and photo(chemo)therapies; these 
therapies were more frequently used for psoriasis (25% and 46%, respectively) than 
for eczema (13% and 13%, respectively). The median duration of follow-up in patients 
with psoriasis was 22.5 years and in eczema patients 20.5 years. During follow-up, a 
total of 535 cancers were diagnosed among patients with psoriasis and 855 among 
patients with eczema.
Psoriasis
The risk of cancer was slightly increased in patient with psoriasis (SIR=1.07; 95% 
CI=0.98-1.16) (Table 2). The risk of non-basal cell skin cancer (non-bcc) was 
significantly increased (SIR=1.95; 95% CI=1.56-2.42). Patients with psoriasis also 
showed an increased risk of cancer of the female reproductive organs. In table 3 the 
SIRs for the treatment-independent risk of cancer in psoriasis patients are presented. 
In these ‘untreated’ patients the risk of cancer seems to be increased as well, although 
this is not statistically significant (SIR=1.20; 95%CI=0.95-1.48). A 2.7 fold increased 
risk of lymphomas was observed (SIR=2.66; 95% CI=0.86-6.21); however this result 
is based on small numbers (n=5). The treatment-independent risk of non-bcc skin 
cancer was not significantly increased (SIR = 1.38; 95% CI = 0.60-2.72). Table 4 
presents the SIRs of patients who were treated with coal tar, PUVA and systemic 
therapies. Psoriasis patients who used these therapies had a slightly increased risk 
of cancer, similar to the cancer risk in the total group psoriasis patients and in the 
untreated subgroup. This increased risk of cancer was largely caused by an excess 
of non-bcc skin cancer in these treatment groups. In the group of patients treated 
with systemic therapy, increased risks of overall cancer, non-bcc skin cancer, lung 
cancer and prostate cancer were observed as well.
Table 1   Characteristics of patients in the total cohort and stratified by psoriasis 
or eczema.
Characteristic
Total cohort 
(13,200)
Psoriasis 
(4,315)
Eczema 
(8,885)
Gender (male/female %) 47/53 52/48 45/55
Median age at diagnosis (range) 28.4 yr (0 - 95.7) 31.1 yr (0 - 95.7) 27.2 (0 - 91.4)
Calender period of diagnosis
   1960-1969 (%) 2476 (18.8) 931 (21.6) 1545 (17.4)
   1970-1979 (%) 4160 (31.5) 1575 (36.5) 2585 (29.1)
   1980-1989 (%) 6564 (49.7) 1809 (41.9) 4755 (53.3)
Status at end of follow-up
   Diagnosed with cancer (%) 1048 (7.9) 421 (9.8) 627 (7.1)
   Deceased without cancer (%) 1951 (14.8) 725 (16.8) 1226 (13.8)
   Censored at December, 31, 2003 (%) 9346 (70.8) 2840 (65.8) 6506 (73.2)
   Lost to follow-up (%) 855 (6.5) 329 (7.6) 526 (5.9)
 Median duration follow-up (yr) 21 22.5 20.5
   1 - 9 yr (%) 1433 (10.9) 502 (11.6) 928 (10.5)
   10 - 19 yr (%) 4634 (35.1) 1219 (28.3) 3414 (38.4)
   20 - 29 yr (%) 4415 (33.4) 1528 (35.4) 2856 (32.5)
   >30 yr (%) 2718 (20.6) 1063 (24.6) 1654 (18.6)
Severity of skin disease (% area affected)
   <1% 20.9 8.7 26.8
   2-9% 34.3 29.9 36.4
   10-30% 29.6 39.3 25.0
   >30% 15.2 22.1 11.8
Use of other therapies (%)
Topical
   Dermatocorticosteroids 96.6 96.6 96.5
   Vitamin D3 analogues 11.5 32.4 -
   Topical calcineurin-inhibitors                  1.9 1.0 2.4
   Dithranol 3.4 10.2 -
   Coal tar 61.1 71.4 56.1
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Eczema
A slightly increased risk of overall cancer was observed in patients with eczema 
(SIR=1.09; 95% CI=1.01-1.16) (Table 2). The SIR of non-bcc skin cancer was 1.14 
(95% CI: 0.90-1.42); this was lower compared to psoriasis patients (SIR=1.95; 95% CI: 
1.56-2.42). Increased risks were observed for lymphomas, haematological 
malignancies (leukemia), brain tumours, lung cancer and cancer of the female 
reproductive organs. The treatment-independent cancer risk in eczema patients was 
non-significantly increased (SIR=1.10; 95%CI=0.98-1.22) (Table 3). Also, non-signifi-
cantly increased risks of brain tumours, lung cancer and gastrointestinal cancer were 
observed in untreated eczema patients. 
As only a small number of eczema patients were treated with PUVA (n=550) and 
subsequently the number of observed tumours was low, no cancer site-specific 
analyses were performed. The cancer risk in patients with eczema treated with PUVA 
was increased (SIR = 1.33 (95% CI=1.02-1.81)). Patients with eczema who were treated 
with coal tar ointments had a slightly increased risk of cancer (SIR = 1.11; 95% 
CI=1.01-1.22). The risk of gastrointestinal cancer was decreased in patients treated with 
coal tar (SIR=0.76; 95%CI=0.58-0.97). In the group of patients treated with systemic 
therapy, increased risks of overall cancer (SIR=1.36; 95% CI=1.11-1.64) were observed, 
caused by an excess of non-bcc skin cancer (SIR=2.19; 95% CI=1.25-3.55) and cancer 
of the female reproductive organs (SIR=2.29; 95% CI=1.22-3.91).
Table 1   Continued.
Characteristic
Total cohort 
(13,200)
Psoriasis 
(4,315)
Eczema 
(8,885)
Systemic 17.1 25.4 13.1
   Methotrexate 5.2 14.9 0.5
   Retinoids 4.9 13.2 -
   Cyclosporin 1.7 3.5 0.8
   Fumarates 1.8 5.1 -
   Prednison 9.6 5.1 11.8
Photo(chemo)therapie 23.4 45.7 12.5
   PUVA 13.1 27.2 6.2
   UVB 16.7 33.5 8.6
   Goeckerman 3.5 9 0.9
 *  Percentages are based on the part of the cohort that returned the questionnaire (5,530, 1,962 and 3,568 
in the total cohort, in patients with psoriasis and in patients with eczema, respectively)
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Discussion
Our study showed that patients with psoriasis or eczema have an approximately 10% 
increased risk of cancer. Most studies that investigated the risk of overall cancer in 
patients with psoriasis showed increased risks of cancer, with SIRs varying from 1.3 
to 1.8.5-8;10 However, Lindelöf and Bhate et al. showed no increased risk of non-skin 
malignancies in patients with psoriasis.9;26  Two studies that investigated the risk of 
cancer among hospitalized patients with atopic eczema reported increased risks of 
overall cancer (SIR=1.1; 95%CI=1.0-1.3 and SIR=1.5; 95%CI=1.2-1.9, respectively).15;16 
The treatment-independent risk of cancer was slightly increased in both patients with 
psoriasis and eczema. This result suggests that the underlying skin disease itself 
might be a risk factor for development of cancer. A possible explanation for this 
increased risk may be the chronic state of inflammation in these skin diseases. Today, 
the association between chronic inflammation and cancer has been widely accepted, 
but all mechanisms involving this relationship have not fully been resolved yet.27;28  It 
can be assumed that the subgroup of untreated patients will have less severe skin 
disease compared to patients treated with systemic therapy and phototherapy. It is 
possible that patients with mild to moderate psoriasis or eczema have a less disturbed 
immune system compared to patients with a severe skin disease. This could be the 
reason that the intrinsic risk of cancer in the untreated patients was only slightly 
increased. 
The increased risk of cancer in all patients with psoriasis was caused by an increased 
risk of non-bcc skin cancer and haematological malignancies, brain cancer and lung 
cancer in patients with eczema. The risk of cancer of the female reproductive organs 
was increased in both patient groups. Some of the increased cancer risks may be 
explained by the use of carcinogenic treatments, such as the increased risk of 
non-bcc skin cancer in patients with psoriasis treated with PUVA and systemic 
therapies. An association between long-term use of PUVA or cyclosporine and 
non-melanoma skin cancer has been shown in studies before.29-32 Other cohort 
studies in psoriasis patients also observed an increased risk of non-melanoma skin 
cancer.5-10 Most of these studies included hospitalized patients and therefore, it can 
be assumed that the majority of these patients have been treated with phototherapy 
or systemic therapies. 
Also, the increased risk cancer of the female reproductive organs may be therapy 
related. From studies in renal transplant recipients it is known that female recipients 
have a high risk to develop human papillomavirus (HPV) related anogenital (pre)
malignancies, such as cervical and vulvar cancer.33 Immunosuppressive medication T
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Table 4   Standardized incidence ratios (SIR) with 95% confidence intervals  
(95% CI) in the subgroup of patients who were treated with coal tar , 
PUVA or systemic therapies (these patients could also have been 
treated with other therapies).
 Coal tar PUVA Systemic therapy
 Psoriasis (n=3,081) Eczema (n=4,981) Psoriasis (n=1,175) Psoriasis (n=1,096) Eczema (n=1,164)
Cancer type Obs Exp SIR (95% CI) Obs Exp SIR (95% CI) Obs Exp SIR (95% CI) Obs Exp SIR (95% CI) Obs Exp SIR (95% CI)
Overall 383 347.0 1.10 (1.00 - 1.22) 451 405.9 1.11 (1.01 - 1.22) 129 112.3 1.15 (0.99 - 1.37) 156 123.8 1.26 (1.07 - 1.47) 107 78.6 1.36 (1.11 - 1.64)
Skin 63 29.8 2.11 (1.62 - 2.70) 46 36.6 1.26 (0.92 - 1.68) 27 10.0 2.70 (1.78 - 3.93) 33 10.6 3.10 (2.14 - 4.36) 16 7.3 2.19 (1.25 - 3.55)
Hematological 15 10.2 1.47 (0.82 - 2.42) 21 12.7 1.65 (1.03 - 2.53) 7 3.7 1.91 (0.76 - 3.93) 3 3.8 0.80 (0.16 - 2.33) 0 2.8 -
Lymphoma 13 10.6 1.22 (0.65 - 2.09) 18 12.5 1.43 (0.85 - 2.27) 4 3.4 1.17 (0.32 - 3.01) 5 3.8 1.33 (0.43 - 3.10) 4 2.4 1.65 (0.44 - 4.23)
Bone and soft tissue 2 3.5 0.58 (0.07 - 2.10) 3 4.6 0.65 (0.13 - 1.91) 2 1.3 1.56 (0.18 - 5.64) 3 1.3 2.36 (0.47 - 6.90) 1 1.0 0.97 (0.01 - 5.40)
Brain 0 4.4 - 10 5.5 1.81 (0.86 - 3.32) 1 1.7 0.59 (0.01 - 3.31) 0 1.7 - 0 1.3 -
Glands3 4 2.5 1.63 (0.44 - 4.18) 5 3.3 1.52 (0.49 - 3.55) 1 0.9 1.12 (0.01 - 6.25) 1 0.9 1.12 (0.01 - 6.25) 3 0.7 4.11 (0.83 - 12.0)
Head and neck 12 11.3 1.06 (0.55 - 1.85) 20 12.9 1.55 (0.95 - 2.39) 5 3.8 1.31 (0.42 - 3.05) 5 4.1 1.22 (0.39 - 2.84) 6 2.7 2.26 (0.82 - 4.91)
Lung 65 54.3 1.20 (0.92 - 1.52) 86 61.4 1.40 (1.12 - 1.73) 20 16.3 1.23 (0.75 - 1.90) 36 19.0 1.89 (1.32 - 2.62) 13 11.1 1.18 (0.63 - 2.01)
Gastrointestinal 61 73.6 0.82 (0.63 - 1.06) 64 84.3 0.76 (0.58 - 0.97) 12 22.1 0.54 (0.28 - 0.95) 16 25.6 0.63 (0.36 - 1.02) 12 15.0 0.80 (0.41 - 1.40)
Bladder and urinary tract 17 22.6 0.75 (0.44 - 1.20) 24 25.4 0.94 (0.60 - 1.40) 7 6.9 1.01 (0.41 - 2.08) 6 8.0 0.75 (0.27 - 1.64) 9 4.6 1.94 (0.60 - 3.68)
Kidney 7 6.9 1.02 (0.41 - 2.10) 7 7.8 0.90 (0.36 - 1.86) 2 2.3 0.88 (0.10 - 3.17) 3 2.5 1.20 (0.24 - 3.50) 2 1.6 1.28 (0.14 - 4.63)
Prostate 33 28.7 1.15 (0.79 - 1.62) 34 32.3 1.06 (0.73 - 1.47) 12 8.6 1.40 (0.72 - 2.45) 17 9.4 1.80 (1.05 - 2.88) 9 4.8 1.87 (0.85 - 3.54)
Testis 1 1.7 0.58 (0.01 - 3.23) 2 2.4 0.83 (0.09 - 2.99) 1 0.8 1.27 (0.02 - 7.04) 0 0.7 - 0 0.6 -
Breast 47 52.2 0.90 (0.66 - 1.19) 57 62.7 0.91 (0.69 - 1.18) 14 19.2 0.73 (0.40 - 1.23) 16 19.4 0.83 (0.47 - 1.34) 17 13.8 1.23 (0.72 - 1.97)
Female reproductive organs 29 18.3 1.59 (1.06 - 2.28) 51 23.7 2.15 (1.60 - 2.83) 9 6.5 1.39 (0.63 - 2.64) 11 6.9 1.59 (0.79 - 2.84) 13 5.7 2.29 (1.22 - 3.91)
Other 1 1.1 0.95 (0.01 - 5.30) 3 1.3 2.38 (0.48 - 6.96) 0 0.4 - 0 0.4 - 0 0.3 -
Obs =  observed number of tumours
Exp =  expected number of tumours
1  Excluding basal cell carcinoma
2  Includes thyroid, adrenal and salivary glands
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is likely that some tumours were missed, because some types of cancer, such as 
prostate cancer have an indolent behaviour and a part of these patients do not die 
from this tumour. 
 We collected data on potential confounders such as smoking in our cohort. 
However, it is not possible to adjust for these factors in the calculation of standardized 
incidence ratios, because cancer incidence of patients in our cohort was compared 
to cancer incidence in the Dutch population in which these risk factors are not known 
on an individual level.
In conclusion, we demonstrated that patients with psoriasis or eczema have a slightly 
increased risk of cancer, independent of treatment. A possible explanation could be 
the chronic state of inflammation in these skin diseases. Our study also provided 
evidence that the increased risk of cancer in non-bcc skin cancer and cancer of the 
female reproductive organs may be (partly) explained by the use of carcinogenic 
therapies. 
can potentiate oncogenic stimuli, such as HPV leading to mutations in proto-oncogens 
and tumour-suppressor genes. Although dose and duration of the use of systemic 
medication in dermatological patients differs from renal recipients, it is possible that 
the observed increased risk of cancer of the female reproductive organs in our study 
can be explained by the use of systemic therapy.  
However, it can be questioned whether the increased cancer risks after treatment 
with PUVA and systemic therapies can be entirely explained by treatment. As said 
earlier, these patients will have a more severe skin disease compared to the untreated 
group of patients. It may be possible that patients with severe psoriasis or eczema 
have a more disturbed immune system and therefore, may have a higher intrinsic risk 
of cancer compared to patients with less severe skin disease. 
An increased risk of lung cancer in patients with psoriasis and eczema was observed 
in both the non-treatment group and in patients treated with coal tar ointments or 
systemic therapies, so the risk seems treatment-independent. Other studies reported 
an increased risk of lung cancer in patients with psoriasis or eczema as well.5;7;8;10;15 
Our finding of an increased risk of lung cancer could be due to smoking. Most studies 
showed that patients with psoriasis more frequently smoke compared to the general 
population.34;35 Studies in which the association between smoking and eczema was 
investigated, reported conflicting results.36;37  
The risk of brain cancer was increased in patients with eczema. An increased cancer 
risk was also observed in the subgroup of untreated eczema patients, although these 
results were no longer statistically significant and based on small numbers. Our 
finding is in contrast with results of other case-control studies showing an inverse 
association between atopic eczema and brain cancer.13;17 A recent cohort study of 
Hwang et al. also showed an increased risk of brain cancer in patients with atopic 
eczema (SIR = 2.52; 95% CI = 1.15-4.79).38 
In the analyses on the risk of skin cancer no distinction could be made between the 
risk of melanoma and squamous cell skin carcinoma, because this subdivision could 
not be made in the data from the questionnaire. Basal cell carcinomas are not 
registered in the Netherlands Cancer Registry and therefore, we could not include 
this type of skin cancer in our analyses. 
 Cancer occurrence was assessed by linkages to the Netherlands Cancer 
Registry (NCR), Causes of Death Registry of Statistics Netherlands and information 
from the questionnaires and medical files. Data from the NCR are complete and of 
good quality. For patients who died before 1989 information on cancer occurrence 
was assessed by linkage to the Causes of Death Registry of Statistics Netherlands. It 
104 105
Risk of cancer risk in a cohort of patients with psoriasis or eczema Chapter 5.1
5
27.  Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-7.
28.  Lu H, Ouyang W, Huang C. Inflammation, a key event in cancer development. Mol.Cancer Res. 2006; 
4: 221-33.
29.  Archier E, Devaux S, Castela E et al. Carcinogenic risks of psoralen UV-A therapy and narrowband 
UV-B therapy in chronic plaque psoriasis: a systematic literature review. J.Eur.Acad.Dermatol.Venereol. 
2012; 26 Suppl 3: 22-31.
30.  Arellano F. Risk of cancer with cyclosporine in psoriasis. Int.J.Dermatol. 1997; 36 Suppl 1: 15-7.
31.  Marcil I, Stern RS. Squamous-cell cancer of the skin in patients given PUVA and ciclosporin: nested 
cohort crossover study. Lancet 2001; 358: 1042-5.
32.  Paul CF, Ho VC, McGeown C et al. Risk of malignancies in psoriasis patients treated with cyclosporine: 
a 5 y cohort study. J.Invest Dermatol. 2003; 120: 211-6.
33.  Meeuwis KA, van Rossum MM, van de Kerkhof PC et al. Skin cancer and (pre)malignancies of the 
female genital tract in renal transplant recipients. Transpl.Int. 2010; 23: 191-9.
34.  Huerta C, Rivero E, Rodriguez LA. Incidence and risk factors for psoriasis in the general population. 
Arch.Dermatol. 2007; 143: 1559-65.
35.  Naldi L, Chatenoud L, Linder D et al. Cigarette smoking, body mass index, and stressful life events as 
risk factors for psoriasis: results from an Italian case-control study. J.Invest Dermatol. 2005; 125: 61-7.
36.  Montnemery P, Nihlen U, Lofdahl CG et al. Prevalence of hand eczema in an adult Swedish population 
and the relationship to risk occupation and smoking. Acta Derm.Venereol. 2005; 85: 429-32.
37.  Thyssen JP, Linneberg A, Menne T et al. The effect of tobacco smoking and alcohol consumption on 
the prevalence of self-reported hand eczema: a cross-sectional population-based study. Br.J.Dermatol. 
2010; 162: 619-26.
38.  Hwang CY, Chen YJ, Lin MW et al. Cancer risk in patients with allergic rhinitis, asthma and atopic 
dermatitis: A nationwide cohort study in Taiwan. Int.J.Cancer 2012; 130: 1160-7.
References
1.  Nestle FO, Kaplan DH, Barker J. Psoriasis. N.Engl.J.Med. 2009; 361: 496-509.
2.  Sabat R, Philipp S, Hoflich C et al. Immunopathogenesis of psoriasis. Exp.Dermatol. 2007; 16: 779-98.
3.  Gelfand JM, Berlin J, Van VA et al. Lymphoma rates are low but increased in patients with psoriasis: 
results from a population-based cohort study in the United Kingdom. Arch.Dermatol. 2003; 139: 
1425-9.
4.  Gelfand JM, Shin DB, Neimann AL et al. The risk of lymphoma in patients with psoriasis. J.Invest 
Dermatol. 2006; 126: 2194-201.
5.  Hannuksela-Svahn A, Pukkala E, Laara E et al. Psoriasis, its treatment, and cancer in a cohort of 
Finnish patients. J.Invest Dermatol. 2000; 114: 587-90.
6.  Margolis D, Bilker W, Hennessy S et al. The risk of malignancy associated with psoriasis. Arch.
Dermatol. 2001; 137: 778-83.
7.  Boffetta P, Gridley G, Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for 
psoriasis in Sweden. J Invest Dermatol 2001; 117: 1531-7.
8.  Frentz G, Olsen JH. Malignant tumours and psoriasis: a follow-up study. Br.J.Dermatol. 1999; 140: 
237-42.
9.  Lindelof B, Eklund G, Liden S et al. The prevalence of malignant tumors in patients with psoriasis. 
J.Am.Acad.Dermatol. 1990; 22: 1056-60.
10.  Olsen JH, Moller H, Frentz G. Malignant tumors in patients with psoriasis. J.Am.Acad.Dermatol. 1992; 
27: 716-22.
11.  Bieber T. Atopic dermatitis. N.Engl.J.Med. 2008; 358: 1483-94.
12.  Talbot-Smith A, Fritschi L, Divitini ML et al. Allergy, atopy, and cancer: a prospective study of the 1981 
Busselton cohort. Am.J.Epidemiol. 2003; 157: 606-12.
13.  Wang H, Diepgen TL. Is atopy a protective or a risk factor for cancer? A review of epidemiological 
studies. Allergy 2005; 60: 1098-111.
14.  Soderberg KC, Hagmar L, Schwartzbaum J et al. Allergic conditions and risk of hematological 
malignancies in adults: a cohort study. BMC.Public Health 2004; 4: 51.
15.  Hagstromer L, Ye W, Nyren O et al. Incidence of cancer among patients with atopic dermatitis. Arch.
Dermatol. 2005; 141: 1123-7.
16.  Olesen AB, Engholm G, Storm HH et al. The risk of cancer among patients previously hospitalized for 
atopic dermatitis. J.Invest Dermatol. 2005; 125: 445-9.
17.  Linos E, Raine T, Alonso A et al. Atopy and risk of brain tumors: a meta-analysis. J.Natl.Cancer Inst. 
2007; 99: 1544-50.
18.  Arana A, Wentworth CE, Fernandez-Vidaurre C et al. Incidence of cancer in the general population and 
in patients with or without atopic dermatitis in the U.K. Br.J.Dermatol. 2010; 163: 1036-43.
19.  Castaing M, Youngson J, Zaridze D et al. Is the risk of lung cancer reduced among eczema patients? 
Am.J.Epidemiol. 2005; 162: 542-7.
20.  Melbye M, Smedby KE, Lehtinen T et al. Atopy and risk of non-Hodgkin lymphoma. J.Natl.Cancer Inst. 
2007; 99: 158-66.
21.  Prizment AE, Folsom AR, Cerhan JR et al. History of allergy and reduced incidence of colorectal 
cancer, Iowa Women’s Health Study. Cancer Epidemiol.Biomarkers Prev. 2007; 16: 2357-62.
22.  Roelofzen JHJ, Aben KKH, Oldenhof UTH et al. No Increased Risk of Cancer after Coal Tar Treatment 
in Patients with Psoriasis or Eczema. J Invest Dermatol 2009; 130: 953-61.
23.  Ronckers, C. M. Long-term health effects of nasopharyngeal radium irradiation; a retrospective study 
in the Netherlands.  124-125. 2001. Ref Type: Thesis/Dissertation
24.  Rothman KJ, Greenland S. Modern Epidemiology, 2nd edn edn. Philadelphia: Lippincott 
Williams&Wilkins, 1998.
25.  Gardner MJ, Altman DG. Statistics With Confidence. Confidence Intervals and Statistical Guidelines. 
Belfast: The Universities Press, 1989: 59-60.
26.  Bhate SM, Sharpe GR, Marks JM et al. Prevalence of skin and other cancers in patients with psoriasis. 
Clin.Exp.Dermatol. 1993; 18: 401-4.
6
PAH metabolism in skin after 
application of coal tar
6.1
DNA adducts in skin biopsies and 
1-hydroxypyrene in urine of 
psoriasis patients and healthy volunteers 
following treatment with coal tar
J.H.J. Roelofzen
P.G.M. van der Valk
R. Godschalk
G. Dettbarn
A. Seidel
L. Golsteijn
R. Anzion
K.K.H. Aben
F.J. van Schooten
L.A.L.M. Kiemeney
P.T Scheepers
Toxicol Lett 2012; 213(1):39-44
110 111
PAH metabolism in skin after application of coal tarChapter 6.1
6
Introduction
Coal tar is one of the oldest topical treatments in dermatology. Nowadays, it is still 
used by dermatologists in the treatment of eczema and psoriasis.1 It contains more 
than 10,000 compounds, including polycyclic aromatic hydrocarbons (PAH) in high 
concentrations.2 Some PAH, such as benzo(a)pyrene are classified as human 
carcinogens,3 based on both animal studies4-6 and occupational studies5;7-9, that 
demonstrated associations between PAH exposure and lung, skin and bladder 
cancer. Surprisingly, only few studies have investigated the iatrogenic risk of cancer 
in patients treated with coal tar. Moreover, the majority of these studies did not 
observe an increased risk of cancer.10-14 Only Stern et al. found an increased risk of 
non-melanoma skin cancer in patients treated with coal tar.15 Recently, we performed 
a large historical cohort study in 13,000 patients with psoriasis and eczema to study 
the risk of cancer after dermatological treatment with coal tar ointments (CTO).16 This 
study showed that treatment with coal tar did not increase the risk of squamous cell 
or melanoma skin cancer, nor the risk of non-skin malignancies. 
Differences in cancer risks observed in occupational studies versus studies in 
patients may be explained by the frequency, level and duration of PAH exposure. 
Malignancies have occurred after prolonged occupational exposures, whereas the 
use of coal tar in dermatological practice is limited to a much shorter duration of 
exposure.17;18 Possibly, the body (and especially the skin) is capable of repairing 
tissue damage, following short-term exposure to PAH, but not to the same extent in 
situations of long-term exposure. 
PAH require metabolic activation to exert their carcinogenic effects. Metabolic 
activation can lead to the formation of diol epoxides, which react with DNA to form 
PAH-DNA adducts, and these were found to be pro-mutagenic.6;19 Benzo(a)pyrene 
diol epoxide DNA adducts (BPDE DNA-adducts) are often used as biomarkers of the 
local balance between bioactivation and detoxification. 
A variety of detoxification pathways, including hydroxylation to phenols by cytochrome 
P450 isoenzymes (CYP), conjugation of epoxides and diol epoxides with glutathione 
by glutathione S-transferases, and glucuronidation of diols by UDP-glucuronosyl-
transferases are competing with this PAH metabolic activation.20;21 In many studies 
the role of polymorphisms in the genes coding for these enzymes, as modifiers of 
cancer risk in people exposed to PAH, was investigated. The results of these studies 
are inconsistent, but certain genotypes, such as GSTM1 null genotype have been 
found to lead to accumulation of p53 protein in CTO treated skin22 and a higher risk 
of cancer.23-25 
Abstract
Coal tar ointments (CTO) are frequently used in the treatment of psoriasis and 
eczema, but CTO contain carcinogenic polycyclic aromatic hydrocarbons (PAH). 
PAH are absorbed and metabolized in the skin. In psoriasis, the skin barrier is altered 
and therefore, absorption and metabolism of PAH may differ from healthy skin. In this 
study, levels of urinary 1-hydroxypyrene and PAH-DNA adducts in the skin were 
studied in psoriatic patients and healthy volunteers. Three punch biopsies were taken 
from the lower back of 10 male volunteers and from a psoriatic plaque in 10 male 
patients. A surface of 6.25 cm2 was treated with CTO. After 96 hours CTO was 
removed and another three skin biopsies were collected from the treated area. DNA 
was isolated from skin biopsies and urine was collected during and after the exposure 
period. After 24 h, a twofold lower 1-hydroxypyrene urinary excretion was observed in 
patients compared to healthy volunteers and after 48 h, this difference reached 
statistical significance (p < 0.05). Over 96 h the median level of the sum of PAH-DNA 
adducts, analyzed by 32P-post-labeling, increased from 3.5 before CTO administration 
to 21.1 adducts per 108 nucleotides in volunteers, and from 1.0 to 3.6 adducts per 108 
nucleotides in patients. At 96 h, PAH-DNA levels were higher in healthy volunteers 
than in patients (p < 0.05). Biomarkers for uptake, bioavailability and bioactivation of 
PAH were lower in patients compared to volunteers. These data suggest a lower risk 
of carcinogenic effects of CTO in psoriatic skin compared to healthy skin. 
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Materials and Methods
Study population
The study population consisted of ten healthy male volunteers and ten male patients 
with psoriasis. Patients and controls were selected from a research database of the 
department of Dermatology at the Radboud University Nijmegen Medical Centre, 
The Netherlands. The study persons received an information letter describing the 
objectives and instructions for the study. All persons were invited to visit the outpatient 
clinic of the department of Dermatology twice. All patients had chronic stable plaque 
psoriasis. Four patients did not use any therapy and six patients were treated with 
topical therapies (3 patients with emollients, two patients with a corticosteroid 
ointment and one patient with calcipotriol ointment). The patients with psoriasis were 
asked to stop the use of ointments two weeks before the start of the study (washout 
period). None of the patients used any systemic therapy. The psoriasis area and 
severity index (PASI) was used to assess the clinical severity of psoriasis. Self- 
administered questionnaires were used to obtain information on PAH sources (other 
than the CTO application), such as smoking, diet and indoor air quality. The study 
protocol was approved by the regional medical ethics committee (CMO Arnhem- 
Nijmegen). Written informed consent was obtained from each person before data 
and sample collection was started.
Skin biopsies and application of CTO
Before the CTO was applied, three 4 mm punch biopsies were taken from the lower 
back after local anaesthesia with xylocaine/adrenaline (1:100,000 v/v). Biopsy samples 
were immediately frozen and subsequently stored at -80°C. Subsequently, 1.75 g of 5% 
crude CTO (pix lithantracis in zinc oxide paste) was applied to an area of 2.5 by 2.5 cm 
of the lower back of the volunteers (not at the biopsy location). The content of pyrene 
and benzo(a)pyrene in the CTO was 331.3 μg/g and 263.4 μg/g, respectively. In patients 
with psoriasis CTO was applied on a psoriatic plaque of the same area size (2.5 x 2.5 
cm). CTO was applied in excess, covered with waterproof adhesive tape (Allevyn 
adhesive®, Smith & Nephew, Engeland) and fixed with Tegaderm Film® (3M Health 
Care, the Netherlands) (Figure 1). After 96 h the adhesive tape and CTO were removed 
during a second visit to the outpatient clinic. Subsequently, three punch biopsies were 
taken from the area that had been treated with CTO.
Urine sample collection
For each subject a urine sample was collected before CTO was applied to establish 
the baseline excretion of 1-OHP. The following four days (96 h) spot urine samples 
were collected twice daily (in the morning between 7 a.m. and 9 a.m. and in the 
evening between 7 p.m. and 9 p.m.) until CTO was removed.  
Both in the dermatological and occupational setting, the skin is an important route of 
uptake.26;27 After exposure via the skin, 1-hydroxypyrene (1-OHP), the principal 
metabolite of pyrene, can be used as a biomarker for the assessment of dermal 
uptake and bioavailability of PAH.28 In studies concerning occupational exposure, 
e.g., in the production of coke, carbon products and aluminum, elevated urinary 
levels of 1-OHP after PAH exposure were detected.29-31 In several studies the urinary 
excretion of 1-OHP in patients with atopic eczema and psoriasis treated with coal tar 
was investigated.18;32-38 In all of these studies high levels of urinary 1-OHP were 
observed after dermal application of coal tar. 
Psoriasis is a chronic inflammatory skin disease, characterized by hyperproliferation 
of keratinocytes, leading to thickening of the epidermis, including the stratum 
corneum (hyperkeratosis). In addition, the intracellular lipid content was altered, 
resulting in reduced permeability for lipohilic substances.39 Changes in this barrier 
function may lead to an increased or decreased permeability of components in 
ointments. Barrier function changes of the epidermis in psoriasis will depend on the 
activity of psoriasis. A study of Ghadially et al. showed that the barrier function was 
much more disturbed in active plaque psoriasis, compared to chronic plaque 
psoriasis.40 
Besides altered permeability of the skin, metabolism of PAH may be changed in 
patients with psoriasis. A study of Chapman et al. reported a reduced activity and 
inducibility of aryl hydrocarbon hydroxylase (AHH), a microsomal mono-oxygenase 
in skin from psoriatic patients compared to healthy controls after incubation with 
benza(a)nthracene. Since AHH converts many PAH to active metabolites, the authors 
suggest that patients with psoriasis have a lower risk of skin cancer.41 However it is 
not known whether the activity of other PAH metabolizing enzymes differs in psoriatic 
skin compared to the skin of healthy individuals. If PAH metabolism in the skin of 
patients with psoriasis is altered, this could have implications for the carcinogenic 
potential of CTO.
The aim of our study was to investigate differences in dermal absorption of PAH and 
metabolic activation of PAH after topical application of coal tar in patients with 
psoriasis and healthy volunteers, using established biomarkers of internal absorption 
and metabolic activation.
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Analysis of urinary 1-OHP 
The analytical procedure to determine urinary 1-OHP levels in the patients was 
based on the use of reverse-phase high performance liquid chromatography with 
fluorescence detection and has been described previously.43 Determination of 1-OHP 
in the urine samples of volunteers was performed using a GC-MS/MS methodology 
including a derivatization step to give 1-methoxypyrene as previously reported.44 
Creatinine determined according to the Jaffé method was used to adjust for the 
variability in urine density. 
Statistical analysis
The characteristics of the study groups were summarized by descriptive methods. To 
compare means of PAH-DNA levels before and after application of CTO, 
non-parametric Wilcoxon signed rank tests were performed. Mann-Whitney U tests 
were used to compare median DNA adduct levels between patients and volunteers 
and between smokers and non-smokers. Pearson correlation coefficients were used 
to evaluate associations between the sum of PAH and BPDE-DNA adducts. In all 
analyses a p-value of < 0.05 was considered statistically significant. Analyses were 
performed using SPSS software, version 16 (SPSS, Chicago, IL, USA).
Results
The mean age of the healthy volunteers (28 y; range 18-68 y) was lower compared to 
the patients with psoriasis (60 y; range 36-74 y). The number of smokers was 
comparable in the group of volunteers and psoriasis patients (3/10 and 2/10, 
respectively). Smokers in both study groups reported a mean number of cigarettes of 
9-16/day. The mean PASI-core in patients with psoriasis was 7.2, indicating a mild to 
moderate psoriasis. 
The urinary concentrations of 1-OHP in volunteers and patients with psoriasis before 
and during CTO exposure are presented in Figure 3. In both study groups, the highest 
concentration of urinary 1-OHP excretion was observed at 36-48 h after CTO 
application. At t = 48 h, the difference in excretion of 1-OHP between volunteers and 
patients was statistically significant (p < 0.05). No statistically significant difference in 
urinary concentrations of 1-OHP was observed between volunteers and patients 
before CTO application (t = 0) and after 96 h. 
In Table 1 the results are presented for the PAH-DNA and BPDE-like DNA adduct 
levels in skin biopsies of volunteers and patients, before CTO application and after 96 
hours of CTO exposure. Before the application of CTO, BPDE like adducts (expressed 
32P Postlabelling of DNA adducts
The 32P-postlabelling assay was performed as described earlier.42 Adduct levels 
were expressed as adducts that migrated to the same position as the BPDE-DNA 
adduct standard or as the sum of all detectable DNA-adducts (see Figure 2). In each 
experiment, parallel analyses were run for the three calibration standards of [3H]-
BPDE-modified DNA with known modification levels (1 per 106, 107 and 108 
nucleotides).
Figure 1   Application of CTO to an area of 2.5 by 2.5 cm on the forearm of a patient 
with psoriasis. After application of CTO the treated area was covered with 
waterproof adhesive tape.
Figure 2   32P-post-labeling chromatograms of untreated skin (A) and skin treated 
with coal tar ointment (B). The major DNA adduct spot (indicated by arrow 
in panel B), migrated to the same position as the BPDE-DNA adduct 
standard. Chromatograms were similar for psoriasis patients and healthy 
volunteers
A B
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as medians and ranges in adducts per 108 nucleotides) were below the detection limit 
in both study groups. These adducts levels increased to 8.2 (3.9-13.3) at 96 h in 
volunteers, but only to 1.1 (0.5-6.7) in patients (p < 0.05).
For the sum of PAH-DNA adducts, there was a small but significant difference in 
adduct levels between patients and volunteers, already before the application of 
CTO. During the exposure period the sum of PAH-DNA adducts (expressed in 
adducts per 108 nucleotides) increased from 3.5 (1.0-5.2) before CTO administration 
to 21.1 (12.9-29.1) in healthy volunteers, and from 1.0 (0.6-2.9) to 3.6 (2.1-18.9) in 
patients. At 96 h, PAH-DNA adduct levels were almost 6-fold higher in healthy 
volunteers than in patients (p < 0.05).
 
The percentage of BPDE-like DNA adducts to the sum of PAH-DNA adducts were 
comparable in both groups (38% versus 31%). At t = 96 h the sum of PAH-DNA and 
BPDE like DNA adducts were strongly correlated in both volunteers and patients 
(Pearson’s correlation coefficients of 0.70 and 0.96, respectively). DNA adduct levels 
were not affected by cigarette smoking in both study groups.
Figure 3   Urinary excretion of 1-hydroxypyrene (error bar indicates standard error of 
the mean). Time = 0 hours, just before the start of application of CTO.
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Another possible explanation is an increased activity of DNA repair systems in 
patients, resulting in removal of adducts from DNA bases, e.g. by nucleotide excision 
repair. We suppose that stress-activated protein kinases like the c-Jun-N-terminal 
kinase (JNK) signal transduction pathway could be involved in activation of the AP1 
proteins that mediate a physiological response to DNA-damage, including induction 
of DNA repair enzyme activity. This pathway is not active in normal skin, but is 
activated in psoriatic epidermis.47;48 However, in our opinion, this is not a very plausible 
explanation since bulky DNA adducts have a life span that goes beyond the duration 
of the study period of 96 h.49
Some methodological issues and limitations of this study will be addressed. The 
number of included study persons is relatively small: ten patients with psoriasis and 
ten healthy volunteers. Nevertheless, results of PAH-DNA adducts and urinary 1-OHP 
excretion point to the same reduction in absorption and bio-activation, indicating that 
the number of subjects in the current study provided sufficient power for these 
biomarkers.
The age distribution of the subjects in the patient and volunteer groups was different: 
the mean age was 2-fold higher in the patients compared to the volunteers. For PAH 
it has been reported that exposure accumulates over time and age was found to be 
associated with the level of excreted 1-OHP in some studies.50 We cannot rule out the 
possibility that age interfered with the study outcome, but these age differences do 
not explain the observed reduced level of 1-OHP excretion in patients. 
In healthy volunteers all punch biopsies were taken from the lower back. This region 
was chosen for cosmetic reasons, because punch biopsies could result in scar 
formation. In patients with psoriasis punch biopsies were taken from a psoriatic 
plaque: forearm in five patients, lower leg in four patients and abdomen in one patient. 
This is not a likely explanation for the observed differences between volunteers and 
patients, since the uptake of PAH between different regions of the body is similar.27 
Six patients were topically treated with ointments, of which three patients with 
corticosteroid or calcipotriol ointments. To eliminate the possible effects of these 
therapies on the study results, a washout period of two weeks was applied.
Our study was limited to benzo(a)pyrene and pyrene as chemical markers of a 
complex PAH mixture that involves several hundred different substances. Although 
these substances are often used as markers for physicochemical and toxicological 
evaluations for this mixture, we cannot rule out the possibility that our findings may 
not reflect the uptake and bioactivation patterns of other relevant and carcinogenic 
substances.
Discussion
In this study several biomarkers of bioavailability and bioactivation of PAH in CTO 
were investigated in patients with psoriasis and in healthy volunteers. PAH-DNA 
adducts were studied in skin biopsies and additionally the excretion of urinary 1-OHP 
was analyzed, reflecting the result of both local and systemic metabolism. Substantial 
differences were observed in patients compared to healthy volunteers. Both urinary 
1-OHP as well as DNA adduct levels were lower in patients with psoriasis, compared 
to healthy volunteers, indicating a reduction in absorption or bioactivation in psoriatic 
skin. Possible mechanisms that could explain the observed differences between 
patients and volunteers will be discussed. 
The most straightforward explanation could be that the structural changes of the 
psoriatic skin are such that it becomes more difficult for the PAH to permeate the skin. 
Psoriatic skin is less lipophilic and therefore less permeable for PAH that have a high 
octanol-water partition coefficient (Log Po/w of 6) .
45 Also, slow uptake could be explained 
by an increased rate of renewal of stratum corneum, resulting in increased peeling off 
flakes of dead cells, including incorporated PAH.46 If the total amounts of cells in 
psoriatic skin is greater compared with healthy skin cellular dose in patients may be 
lower due to distribution of the same amount of administered PAH over a larger number 
of cells. This hypothesis could be tested by also taking biopsies from healthy skin in 
patients. In the study we only looked at the effects in biopsies of psoriatic skin. 
After dermal uptake the lung is the site of second pass metabolism after the skin 
(ACGIH, 2009). This leads to a higher probability that 1-OHP is excreted in urine as a 
glucuronide conjugate (compared with oral uptake of pyrene, which leads to liver 
metabolism and subsequent excretion primarily via bile because of the relative high 
molecular weight of the glucuronidated 1-OHP). 1-OHP should therefore be 
interpreted as an indicator of dermal uptake and bioavailability rather than of (local) 
biotransformation in the skin. Therefore, the observed pattern of urinary excretion 
supports the reduced dermal absorption in patients as the most plausible explanation 
of the differences observed between patients and healthy volunteers. 
 Urinary 1-OHP excretion shows a 2-fold difference, whereas the difference in 
DNA-adducts was 6- to 8-fold (for the sum of PAH and BPDE like DNA adducts, 
respectively), suggesting that other factors than reduced absorption, bioavailability 
and bioactivation may be involved to explain lower biomarker levels in patients. 
A difference may exist in conjugation pathways such as the glutathione-S-transferase 
(GSH) activity. We studied the activity of GSH in the biopsy tissues, but were not able 
to find any differences (results not presented). 
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In this study, 1-hydroxypyrene was used as a biomarker of exposure to CTO and 
reflects both dermal uptake and bioavailability of PAH. No specific marker was used 
to measure only absorption of CTO because attempts to quantitatively extract 
benzo(a)pyrene and pyrene from skin biopsy materials was unsuccessful. In our 
study it was not possible to make a clear distinction between the contribution of local 
and systemic metabolism, but for the formation of DNA-adducts it is likely that local 
bioactivation and repair mechanisms are primarily responsible for the observed 
adduct levels. 
Smoking is a known contributor to formation of DNA adducts.51 The number of 
smokers was small (three volunteers and two patients) and the differences in 
DNA-adduct levels between smokers and non-smokers were not statistically 
significant. It would be worthwhile to study the influence of smoking on the effect of 
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General discussion
This thesis presents the results of the LATER-research project: the LAte effects of 
coal Tar treatment in Eczema and psoriasis; the Radboud study. The main objective 
of this project was to assess the risk of cancer after coal tar treatment in patients with 
psoriasis or eczema. We also aimed to evaluate whether the risk of cancer in patients 
with psoriasis or eczema differs from the general population. Finally, we planned to 
conduct a side study to investigate dermal absorption and metabolism of PAH after 
dermal application of coal tar in psoriasis patients and healthy volunteers. In this 
general discussion the overall results that are presented in this thesis will be evaluated 
and some methodological issues will be addressed. In the last part of this chapter 
possible clinical implications and recommendations for future research will be 
presented.
Evaluation of study results
Risk of cancer after dermatological application of coal tar 
The use of coal tar in dermatological practice has diminished over the past decades. 
Pharmacists are more reluctant to produce coal tar preparations because of stringent 
regulations by the government. Also, dermatologists prescribe coal tar ointments 
less frequent, because of their assumed potential carcinogenic effect (Chapter 3). 
However, substantial scientific evidence is lacking; only a few studies on the risk of 
cancer after coal tar treatment in dermatological patients are available.1-5 These 
studies included only a small number of patients or were not designed to address 
specifically the risk of cancer after coal tar treatment (e.g. patients were also treated 
with UVB or PUVA phototherapy). The LATER-study included 13,200 patients with 
psoriasis or eczema and had sufficient power to investigate the risk of cancer after 
coal tar treatment in these patients. 
We showed that the use of coal tar ointments was not associated with an increased 
risk of non-melanoma skin cancer (Chapter 4.1). We also analyzed the risk of 
non-melanoma skin cancer after coal tar exposure in a high exposure category (pix 
lithantracis) and a low exposure category (liquor carbonis detergens). The risk of skin 
cancer was not significantly increased after the use of liquor carbonis detergens, 
whereas a non-statistically significantly decreased risk was observed in the group of 
patients treated with pix lithantracis. The concentration of PAH in pix lithantracis is 
much higher compared to liquor carbonis detergens. However, the intensity of PAH 
exposure is not only determined by the PAH concentration, but also by the duration 
of exposure. In general, the use of pix lithantracis is largely restricted to a hospital 
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lower levels of urinary 1-OHP and PAH-DNA adducts in patients with psoriasis. The 
barrier function of the skin is also disturbed in patients with eczema, but these 
changes have a different pathophysiology compared to psoriasis. For future research 
it would be very interesting to study absorption and metabolism after coal tar 
application in patients with eczema to investigate whether the differences in patho-
physiology between these two skin diseases will lead to differences in absorption 
and metabolism.   
Risk of cancer in patients with psoriasis or eczema
The risk of cancer in patients with psoriasis and eczema has been studied by many 
authors.6;7;9;16-28 Our results are consistent with the majority of previous studies, 
showing a slightly increased risk of cancer in patients with eczema and psoriasis 
compared to the general population (Chapter 5). 
The majority of patients in these reported studies of cancer risk have been treated 
with several therapies and therefore, it is not possible to exclude the effect of treatment 
on the risk of cancer. Theoretically, it may be possible that patients with psoriasis or 
eczema have an increased risk of cancer, independent of treatment. The chronic 
state of inflammation in these skin diseases could lead to chronic stimulation of cells 
of the immune system, which may lead to randomly occurring pro-oncogenic 
mutations in actively dividing cells.29;30  
 In our study we were able to select a subgroup of patients treated with dermato-
corticosteroids only (of which no increased risk of cancer is assumed). Therefore, we 
were able to study the treatment-independent risk of cancer in patients with psoriasis 
or eczema. 
For both psoriasis and eczema, the overall risk of cancer in patients treated with der-
matocorticosteroids only was borderline increased. These results suggest that 
patients with psoriasis or eczema have a slightly increased risk of cancer, independent 
of therapy. Our results also pointed to an increased risk of lymphomas in patients with 
psoriasis and eczema who were treated with dermatocorticosteroids only. An 
increased risk of lymphomas in psoriasis has been suggested previously, but studies 
that investigated the risk of lymphomas in psoriasis showed conflicting results.6;7;17;20;22;23 
Studies that investigated the association between atopic eczema and the risk of 
lymphomas also showed conflicting results.9;16;21;26;28  It is difficult to compare the 
results of these studies, because the effect of treatment cannot be excluded in these 
studies. In our study, we also included patients with allergic contact eczema and 
irritant contact eczema. These subtypes of eczema have a different pathophysiology 
and therefore, our study and studies in atopic dermatitis are not completely 
comparable.
setting and therefore, used for a shorter period of time compared to the use of liquor 
carbonis detergens. This was confirmed by our study, showing that patients applied 
liquor carbonis detergens for a longer period of time compared to pix lithantracis.
Overall, the risk of non-skin cancer after coal tar was not increased in patients with 
psoriasis or eczema. No differences in cancer risk were observed when stratifying by 
skin disease, except for the increased risk of cancer of the female reproductive 
organs in patients with eczema. In contrast, no increased risk was observed in female 
psoriasis patients. 
In the literature it is suggested that patients with psoriasis and eczema may have an 
increased risk of hematological malignancies, because of the hyperreactive immune 
status in these skin diseases.6-9 Therefore, we considered this type of malignancy a 
tumor risk ‘site’ for coal tar exposure. However, no association between hematological 
malignancies and coal tar treatment was observed in our cohort of patients with 
psoriasis or eczema.
We did not expect the gastrointestinal tract to be a tumor risk site, but the decreased 
risk of gastrointestinal cancer, most pronounced in patients with eczema, was 
unexpected. The observed number of gastrointestinal tumors in our cohort was fairly 
large (n= 203), so there may be another reason than just chance. In the literature, 
very little is known about the risk of gastrointestinal cancer after coal tar exposure. 
Jones reported an increased risk of colon cancer in men, but not in women after coal 
tar treatment in patients with psoriasis. However, these results were based on small 
numbers of gastrointestinal tumors (n=6).1  
No increased risk of bladder cancer was observed after dermatological exposure to 
coal tar. In our case-control study no association was found between bladder cancer 
and the use of coal tar preparations as well (Chapter 4.2). It is known that PAH are 
absorbed and metabolized in the skin after application. Consequently, several 
studies have shown increased 1-hydroxypyrene (1-OHP) levels in urine of patients 
with psoriasis10-12 or eczema13-15 after coal tar application. In our toxicology study, we 
investigated the uptake and bio-activation of PAH in psoriatic patients and healthy 
volunteers after coal tar application (Chapter 6). Increased levels of urinary 1-OHP 
and PAH-DNA levels in skin were observed after coal tar application in both study 
groups. However, 1-OHP levels and PAH-DNA adduct levels were lower in patients 
with psoriasis compared to healthy volunteers, suggesting a reduced absorption and 
activation in psoriatic skin. Hyperkeratosis of the epidermis and alterations in the 
intracellular lipid composition of psoriatic skin changes the barrier function of the 
skin. As a result, the permeability of the skin is changed and this may explain the 
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etanercept, infliximab (tumour necrosis factor-α (TNF-α) antagonists) and ustekinumab 
(interleukin 12/23 monoclonal antibody).36 These therapies have a favorable 
short-term safety profile, but long-term safety data are not yet available. 
Methodological considerations
Study design
The study design of the LATER-study is a historic cohort study. There is a long time 
between exposure and development of cancer and this makes a prospective study 
not feasible. A cohort design was chosen because we were not only interested in the 
occurrence of overall cancer, but also in many site-specific cancers. Therefore, the 
most feasible study design to answer our research questions was a historic cohort 
study. 
Because of the study-design, data in the LATER-study were retrospectively collected. 
Approximately 50% of the patients in the LATER-study were diagnosed with psoriasis 
or eczema in the calendar period 1960-1979. As a consequence, these patients had 
to remember information on their skin diseases and diagnosis of cancer more than 
25 years ago when filling out the questionnaire. However, detailed information was 
collected from the medical files and this was supplemented with information from the 
questionnaires.   
Clear eligibility criteria for inclusion in the cohort were formulated before start of the 
study, and therefore, selection probably not occurred during the initial inclusion of 
patients in the cohort. The amount of information on the occurrence of cancer was 
not the same for all patients in the cohort. For the deceased patients no information 
on cancer was available from the questionnaires. In addition, no information from the 
Netherlands Cancer Registry was available for patients who deceased before 1989 
(introduction of the NCR). This could have caused an underestimation of cancer 
occurrence in the cohort. However, information on cancer occurrence was obtained 
in the same way for patients who were and who were not treated with coal tar, so 
information bias will be unlikely. Also, not all information from the questionnaires may 
be exactly correct, because patients had to remember information on their skin 
disease from the past. However, we assume that this is similar in the coal tar exposed 
and non-exposed patients, i.e. the misclassification will be non-differential.
Use of self reported data from questionnaires
Data on the variables used in our analyses (cancer occurrence, use of coal tar and 
other therapies and several confounders) were recorded from medical files and 
Besides the selection of an ‘untreated’ group of patients, we also selected patients 
who were treated with PUVA and systemic therapies. Our results show that some of 
the observed increased cancer risks may be therapy-related. The risk of non-bcc skin 
cancer was increased in patients with psoriasis (SIR 2.0), but was not significantly 
increased in the subgroup of untreated psoriasis patients, suggesting that the 
increased skin cancer risk can be explained by treatment. This was supported by our 
results showing an increased risk of non-bcc skin cancer in psoriasis patients who 
had been treated with PUVA and systemic therapies. An association between 
non-melanoma skin cancer and long-term use of PUVA and systemic therapies, such 
as cyclosporine, has been shown in several studies before.31-34 
 Also, the risk of cancer of the female reproductive organs in patients with eczema 
that we reported may be therapy-related, because no increased risk of cancer was 
observed in eczema patients treated with dermatocorticosteroids only, while a significantly 
increased risk was found in eczema patients treated with systemic therapies.  
 However, it is possible that the increased cancer risks in patients treated with 
PUVA or systemic therapies cannot be completely explained by these treatments. 
Patients treated with systemic therapies and phototherapy will have a more severe 
skin disease compared to the untreated group of patients. It may be possible that 
patients with severe psoriasis or eczema have a more disturbed immune system and 
therefore, may have a higher intrinsic risk of cancer compared to patients with less 
severe skin disease. 
Psoriasis and eczema often require years of treatment and therefore, it is important to 
consider the efficacy and safety profile when prescribing a therapy. We found an 
increased risk of non-melanoma skin cancer associated with the use of PUVA and 
systemic therapies. In the past years, the use of PUVA has largely been replaced by 
UVB. This was confirmed in our survey among Dutch dermatologists showing that for 
both eczema and psoriasis UVB is more often used than PUVA. The Dutch guidelines 
also advise UVB as first line phototherapy in the treatment of psoriasis and eczema.35;36 
Systemic therapies are often used in the treatment of moderate or severe psoriasis or 
eczema. To reduce cumulative toxicity of these therapies,  several treatment 
strategies, such as rotation therapy (in which different therapies with different safety 
profiles are alternately prescribed) have been used. Combination therapies 
(simultaneously prescribing multiple medications to allow dose reduction of each 
therapeutic modality), or intermittent use (introducing drug-free periods) have also 
been proposed.37-40  However, liver and kidney damage caused by methotrexate, 
cyclosporine or retinoids cannot be completely prevented by these treatment 
strategies. The introduction of the biologic agents about a decade ago has provided 
more options for the short- and long-term treatment of patients with psoriasis. In the 
Netherlands four biologics are registered for the treatment of psoriasis: adalimumab, 
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these techniques often produce biased results.45-47 We used self-reported data on 
smoking habits from the questionnaire, because no information on smoking was 
available from the medical files. A recent study of Wong et al, assessing the validity 
of self-reported cigarette smoking in Canadians, showed high concordance estimates 
(91.6%) between self-reported smoking and urinary cotinine (nicotine-metabolite) 
concentrations.48 However, a systemic review on this topic reported highly variable 
sensitivities (30-100%), depending on the population studied and the medium in 
which the biological sample was measured (urine, saliva or blood).49 
Coal tar: past, present and future
Before the introduction of topical corticosteroids, coal tar ointments were frequently 
used in the treatment of psoriasis and eczema. Coal tar ointments were used as 
monotherapy, in combination with UVB as the Goeckerman therapy or as the Ingram 
regime; a combination of coal tar, dithranol and UVB. Since the introduction of more 
cosmetically accepted ointments such as topical corticosteroids, vitamin D analogues 
and calcineurin inhibitors, the use of coal tar ointments has diminished. However, 
from the results of our survey we can conclude that coal tar ointments still have a 
position in the treatment of eczema, and to a lesser extent in psoriasis. Coal tar 
ointments can be used as an alternative in carefully selected cases for the (long-term) 
use of systemic drugs as prednisone and cyclosporine. Long-term use of prednisone 
can cause osteoporosis, hypertension and corticosteroid-induced diabetes50, 
whereas long-term use of cyclosporine is associated with nephrotoxicity and an 
increased risk of non-melanoma skin cancer and hematological malignancies.32-34 In 
addition, tapering or stopping these systemic therapies often causes an exacerbation 
of the skin disease.
 We realize that the application of coal tar ointments is much more time consuming 
compared to the intake of systemic therapies. However, skin diseases as eczema 
and psoriasis are chronic skin diseases requiring long-term treatment. Besides 
therapy, education of patients with a skin disease must be an important treatment 
goal. If patients are well informed on their skin disease and treatment, the acceptance 
of the skin disease will be better, leading to a higher compliance of therapies. In our 
hospital or day care setting, patients can be trained in coal tar treatment by specialized 
nurses. They provide information on the basic concepts of treatment, advice on 
coping with a chronic skin disease and answer questions of the patients. In our 
opinion, this concept of education and support is very important in the feasibility of 
coal tar treatment.
registries, but also self-reported information from the questionnaires was used. We 
checked whether information on cancer occurrence from the responders to the 
questionnaire correlated with the data on cancer occurrence from the Netherlands 
Cancer Registry. Only 54 patients (<1%) did not report a diagnosis of cancer in the 
questionnaire, but were diagnosed with a tumor in the Netherlands Cancer Registry. 
Almost 5% of the patients reported a diagnosis of cancer in the questionnaire, but 
were not registered with a tumor in the NCR. However, for patients who reported a 
diagnosis of cancer before 1989 (3.3%) this is possible, because the NCR data are 
only complete since 1989. We therefore, think that information on cancer occurrence 
from the self-administered questionnaires is reliable. In the literature, several studies 
have been published in which the validity of self reported diagnosis of cancer was 
investigated.41-44 Data from questionnaires were compared to data from medical 
records or population-based cancer registries. These studies showed differences in 
sensitivity, depending on the type of cancer. In general, breast cancer has the highest 
sensitivity and bladder cancer, colorectal cancer and cancer of the cervix uteri and 
corpus uteri showed the lowest sensitivity. Propably, in case of these latter types of 
cancer doctors often tell patients that they have a ‘benign’ type of cancer and 
therefore, these patients don’t report these forms of cancer. Other factors associated 
with a correct self reported diagnosis of cancer are age, sex and level of education.42;43 
Also, differences have been observed across countries, with the highest level of 
ability to self report cancer in the USA, followed by Europe and lowest in Japan.41-44   
Data on the use of coal tar ointments were collected from the medical records and 
postal questionnaires. Based on information from the medical files, patients were 
included in the study. Therefore, all information on the use of coal tar ointments 
available through these medical files was recorded for all included patients. In 
addition, information on the use of coal tar ointments was collected from the 
questionnaires. Because of the typical color, odor and staining of coal tar ointments, 
it can be assumed that patients will remember the use of coal tar ointments. However, 
only a minority of responders of the questionnaire (20%), filled out the questions on 
the duration of coal tar use. This was analogue to the questions on the duration of all 
other therapies that patients received (local, photo- and systemic therapies). From 
these data we concluded that patients remembered which therapies were prescribed, 
but were not able to remember the duration of these therapies.
Data on smoking habits were only available from the patients with a completed 
questionnaire and were therefore missing in a large proportion of the cohort (58%). To 
handle these missing data, we used a multiple imputation technique.45 This technique 
is preferred over simple techniques for handling missing data, such as complete 
case analysis, overall mean imputation, and the missing-indicator method, because 
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the genes in the activation and detoxification pathways are possible. This will possibly 
complicate the feasibility of such studies.  
Clinical implications of this project
The main objective of the LATER-study was to investigate the risk of cancer after coal 
tar treatment in patients with psoriasis or eczema. So far, the LATER-study is the 
largest study on this topic and therefore, we were able to estimate the risk of cancer 
after coal tar treatment reliably. Our results did not show an association between the 
use of coal tar and an increased risk of non-melanoma skin cancer or internal 
malignancies. This indicates that coal tar has been proven to be a safe treatment in 
dermatological practice. We believe that the LATER-study provided enough evidence 
to take away doubts on the carcinogenicity of coal tar with dermatological use. 
Therefore, coal tar ointments should not be abandoned as a therapeutic option, but 
should be maintained as a second line treatment option for eczema and psoriasis in 
selected patients. 
A second objective of this project was to evaluate whether the risk of cancer in 
patients with psoriasis or eczema differs from the general population. Psoriasis and 
eczema are two chronic skin diseases that require long-term treatment. Therefore, it 
is important that patients with these skin diseases are treated as effective and safely 
as possible. An association between non-melanoma skin cancer and PUVA and 
systemic therapies was observed in our study. These results suggest that these 
therapies should be used with care as long-term therapies. With the introduction of 
biologics in the treatment of psoriasis, an alternative for long-term use of classic 
systemic treatments has become available. The risk of cumulative toxicity associated 
with long-term use of biologics may be less compared to classical systemic therapies. 
However, the costs of treatment with biologics are high and long-term safety data are 
not yet available. When considering topical treatment like tar ointments or systemic 
therapy, such as the biologics, efficacy, cost-effectiveness and safety profiles of the 
therapies should be taken into account. 
In the current guidelines of the Dutch Association for Dermatology and Venereology 
coal tar preparations have a minor position in the treatment of atopic dermatitis35. 
Topical corticosteroids and calcineurin inhibitors are first choice therapies. The 
opinion of the experts is that coal tar preparations can be used when dermatocortico-
steroids or calcineurin inhibitors are not effective or can be added to pulse therapy 
with dermatocorticosteroids. In many international guidelines coal tar no longer has 
a position in the treatment of atopic dermatitis.51;52 In the current national and 
international guidelines, the role of coal tar ointments in the treatment of psoriasis is 
limited.36;53;54 Although coal tar ointments don’t have an important position in the 
treatment of eczema and psoriasis nowadays according to the guidelines, we think 
that coal tar ointments still are a second line therapy for many dermatologists. This 
was confirmed by the data from our survey showing that the majority of dermatologists 
in the Netherlands and Belgian Flanders still prescribe coal tar ointments (Chapter 3).
Future perspectives 
Despite the fact that coal tar ointments have been used for decades for the treatment 
of several skin diseases, the mechanism of action on the cellular level is still unknown. 
Coal tar ointments are a mixture of more than 10,000 components and therefore, it is 
very hard to identify which components are responsible for the biological effect and 
which for carcinogenic effect. Theoretically, it is possible that some components 
have anti-carcinogenic effects and some components have a pro-carcinogenic 
effect. It would be very interesting to disentangle the pathways that are responsible 
for the mechanism of action of coal tar ointments.
PAH are metabolized by cytochrome P450 enzymes to diol epoxides. These reactive 
metabolites are able to bind with DNA to form PAH-DNA adducts, which are pro-
mutagenic.55;56 Detoxification pathways are competing with the activation pathways. 
These pathways include direct hydroxylation to phenols by cytochrome P450 
isoenzymes (CYP), conjugation of epoxides and diol epoxides with glutathione by 
glutathione S-transferases and glucuronidation of diols by UDP-glucuronosyltrans-
ferases.22;57  Many studies have investigated the role of polymorphisms in these 
enzymes as modifiers of cancer risk in people exposed to PAH. The results of these 
studies have been inconsistent58;59, but certain genotypes may lead to a higher risk of 
cancer.60;61 
 In future research it would be interesting to study the effect of these polymorphism 
on the levels of several biomarkers of PAH after coal tar application, such as 
1-hydroxypyrene in urine and PAH-DNA in skin. These studies must include very 
large numbers of study objects, because many combinations of polymorphisms of 
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The efficacy of topical treatment with coal tar in patients diagnosed with psoriasis or 
eczema has been well established. However, coal tar ointments contain numerous 
polycyclic aromatic hydrocarbons (PAHs), which are transformed by the cytochrome 
P450 system into reactive metabolites capable of interaction with DNA. Concern has 
been raised about the carcinogenicity of coal tar treatment in the dermatological 
practice. Treatment of skin disorders by coal tar, however, is effective and probably 
safer than its immunosuppressive topical and oral alternatives and should therefore 
not be banned before proper risk assessment. To study the risk of cancer after coal 
tar treatment, the LATER-study (LAte effects of coal Tar treatment in patients with 
Eczema or psoriasis; the Radboud study) was initiated. Within this research project, 
several sub-studies were conducted.
Position of coal tar in the treatment of psoriasis and eczema 
Chapter 1 gives a short general introduction on the subject of this thesis. Chapter 2 
provides a review of coal tar in dermatology. An overview of the production of 
dermatological coal tar, mechanism of action and indications in dermatological 
practice is presented. Possible short-term and long-term side effects are described. 
Short-term side effects include folliculitis, irritation of the skin, contact allergy and 
phototoxic reactions. Long-term side effects focus on the possible carcinogenicity of 
coal tar. An overview of the literature published so far on this topic is discussed.
Coal tar has been used for decades in the treatment of various skin diseases, but 
over the past years, the use of coal tar ointments in dermatological practice has 
diminished. One of the reasons for the decreased use is the presumed carcinogenic-
ity of coal tar ointments, although empirical data for an increased risk of cancer are 
lacking. Another reason is the difficulty to obtain coal tar preparations from the 
pharmacies, because many governments have developed stringent rules for the 
preparation of coal tar ointments. To evaluate the  current position of coal tar in the 
treatment of psoriasis and eczema, a survey was conducted. In Chapter 3 we present 
the results of this study. A postal survey was conducted among Dutch and Flemish 
dermatologists. The study was performed in The Netherlands and Belgium to get an 
impression concerning the variation between the two countries with respect to the 
use of coal tar ointments. The results showed that almost all dermatologists 
prescribed topical corticosteroids, vitamin D3 analogues and calcineurin inhibitors, 
but also coal tar was still used by the majority of the dermatologists. From this study 
we concluded that coal tar still is an important second line therapy for psoriasis and 
eczema. 
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or eczema to the expected numbers of cancer in the general population. In order to 
obtain the expected number of cancer cases, the national incidence rates stratified 
by sex, 5-year age groups and calendar year groups from the Netherlands Cancer 
Registry were used. We collected data on all therapies that patients received, and 
therefore, it was possible to select a group of patients who were only treated with 
emollients or dermatocorticosteroids. By selecting this group of patients, we were 
able to exclude the effect of treatment on the risk of cancer. 
 The overall risk of cancer was slightly increased in the total cohort of patients with 
psoriasis and eczema. Also, in the subgroup of patients treated with dermatocortico-
steroids only, a slightly increased risk of cancer was observed. This study shows that 
patients with psoriasis and eczema have a slightly increased risk of cancer, 
independent of treatment. 
Toxicology
Coal tar ointments contain high concentrations of polycyclic aromatic hydrocarbons 
(PAH). The skin is an important route of uptake of these PAH after coal tar application. 
After exposure via the skin, 1-hydroxypyrene (1-OHP), the principal metabolite of 
pyrene, can be used as a biomarker for the assessment of dermal uptake and bio-
availability of PAH. Psoriasis is characterized by hyperproliferation of the epidermis, 
leading to thickening of the epidermis and by disturbance of the barrier function. As 
a consequence, the permeability of the skin is altered. In addition, metabolism of 
PAH may be changed in patients with psoriasis. If the permeability of the skin and the 
metabolism of PAH in psoriasis are altered, this could have implications for the 
carcinogenic potential of coal tar ointments. 
 To evaluate possible differences in dermal absorption and metabolism of PAH 
after dermal application of coal tar, we conducted a study in ten patients with psoriasis 
and ten healthy volunteers. In Chapter 6 we report the results of this toxicology study. 
DNA was isolated from skin biopsies before and after 96 hours of coal tar application 
and urine was collected during and after the exposure period. 48 hours after 
application of coal tar, a statistical significantly higher 1-OHP excretion was observed 
in volunteers compared to psoriasis patients. At baseline PAH-DNA adduct levels 
were comparable, but after removal of coal tar, PAH-DNA levels were higher in healthy 
volunteers. These results implicate reduced absorption and bio-activation of PAH in 
patients with psoriasis, suggesting a lower risk of carcinogenic effects of coal 
compared to healthy skin. Future research is needed to explore the cellular 
mechanism that can explain the observed results.
Risk of cancer after coal tar treatment 
Despite the lack of clear evidence of an increased risk of cancer, many dermatologists 
have abandoned the use of coal tar. However, it not justified to abandon this therapy 
before a valid assessment of the risk of cancer has been made. In order to assess the 
risk of cancer after coal tar treatment in patients with psoriasis or eczema, we initiated 
a large historical cohort study, the LATER study (LAte effects of coal Tar treatment in 
Eczema and psoriasis; the Radboud study).  Chapter 4.1 describes the results of this 
study in which 13,200 patients diagnosed with psoriasis or eczema between 1960 
and 1990 were included. Information on skin disease and treatment, possible risk 
factors and cancer occurrence was retrieved from medical files, postal questionnaires 
and medical registries (Netherlands Cancer Registry and Causes of Death registry 
held by Statistics Netherlands). Patients treated with coal tar were compared with a 
reference category of patients treated with dermatocorticosteroids only (assuming to 
carry no increased risk of cancer). Coal tar did not increase the risk of skin cancer or 
internal organ malignancies. From these results we concluded that coal tar can be 
maintained as a safe therapy in the treatment of psoriasis and eczema.
After absorption and metabolisation, several metabolites of coal tar are excreted in 
urine and therefore, an increased risk of bladder cancer may be plausible. The risk of 
bladder cancer in patients treated with coal tar was investigated in a few studies, but 
none of the earlier studies was specifically aimed at the association between 
dermatological application of coal tar ointments and the risk of bladder cancer. In a 
population-based case-control study, addressed in chapter 4.2, we studied the 
association between bladder cancer and the use of coal tar. The study included 
1,387 cases diagnosed with bladder cancer and 3,527 population controls. 
Information on the use of coal tar, occurrence of skin disease and known risk factors 
for bladder cancer was obtained through postal questionnaires. No association was 
found between the use of coal tar ointments and an increased risk of bladder cancer. 
Risk of cancer in patients with psoriasis and eczema
Psoriasis and eczema are common, inflammatory skin diseases in which a 
hyperreactive immune system leads to chronic inflammation. Because of the chronic 
stimulation of cells of the immune system, patients may have an intrinsic increased 
risk of malignancies. So far, many studies have investigated the risk of cancer in 
psoriasis and eczema. Many of the patients in these studies were treated with 
carcinogenic therapies, such as cyclosporine and PUVA and as a result, it was not 
possible to exclude the effect of treatment on the risk of cancer in patients with 
psoriasis or eczema in these studies.
 Chapter 5 describes our cohort study in which the risk of cancer was assessed 
by comparing the number of observed cancers in the cohort of patients with psoriasis 
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Conclusions
The main conclusions of this thesis can be summarized as follows:
 -  Coal tar still is an important second line treatment for psoriasis and eczema. 
(Chapter 3)
-  The most important reasons for the diminished use of coal tar are difficulties to 
obtain coal tar preparations from pharmacies and the possible carcinogenicity 
of coal tar. (Chapter 3).
-  Patients with psoriasis or eczema treated with coal tar preparations have no 
increased risk of cancer. (Chapter 4)
-  The use of coal tar ointments in dermatological practice is not associated with an 
increased risk of bladder cancer (Chapter 4)
-  Patients with psoriasis or eczema have a slightly increased risk of cancer, 
independent of treatment (chapter 5)
-  Uptake, bioavailability and bio-activation of PAH in patients with psoriasis differ 
from healthy volunteers (Chapter 6).
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Koolteerzalven zijn in de afgelopen decennia vaak toegepast als behandeling van 
psoriasis en eczeem. Echter, koolteer bevat vele polycyclische aromatische koolwa-
terstoffen (PAKs) die door het cytochroom P450 systeem worden omgezet in reactieve 
metabolieten die kunnen reageren met DNA. Daarom is de afgelopen jaren 
ongerustheid ontstaan over de mogelijke carcinogeniteit van koolteerzalven als 
behandeling van huidziekten. Belangrijk hierbij is wel dat een aantal van de 
alternatieve topicale en systemische behandelingen voor psoriasis en eczeem 
potentieel carcinogeen zijn. Omdat koolteerzalf wel een effectieve therapie is, moet 
eerst grondig onderzoek worden gedaan naar de mogelijke risico’s bij dermatologisch 
gebruik van koolteer voordat deze uit het therapeutisch arsenaal worden geschrapt. 
Om het risico op kanker na het gebruik van koolteerzalf te onderzoeken, is de 
LATER-studie (Late effecten van koolteer behandeling in patiënten met eczeem of 
psoriasis; de Radboud studie) gestart. Binnen dit onderzoeksproject zijn diverse 
substudies uitgevoerd. 
Plaatsbepaling van koolteer in de behandeling van psoriasis  
en eczeem
Hoofdstuk 1 geeft een korte introductie over het onder het onderwerp van dit 
proefschrift. 
 Vervolgens wordt in hoofdstuk 2 een review over koolteer beschreven. Er wordt 
een overzicht gegeven van de productie van koolteer, het werkingsmechanisme en 
indicaties in de dermatologische praktijk. Ook wordt aandacht besteed aan de korte- 
en lange termijn bijwerkingen die als gevolg van koolteer behandeling kunnen 
optreden. Bijwerkingen die na korte tijd kunnen ontstaan zijn folliculitis, huidirritatie, 
contactallergieën en fototoxische reacties. De belangrijkste bijwerking die op 
lange-termijn zou kunnen optreden is het ontstaan van kanker. In het laatste deel van 
het review  wordt een overzicht gegeven van de studies die tot dusver over dit 
onderwerp werden gepubliceerd. 
Koolteer wordt al decennia gebruikt bij de behandeling van huidziekten, maar het 
gebruik van deze zalven is in de afgelopen jaren verminderd. Eén van de redenen 
hiervoor is de veronderstelde carcinogeniteit alhoewel overtuigend bewijs hiervoor 
ontbreekt. Een andere reden voor het afgenomen gebruik is de moeizame verkrijg-
baarheid van koolteer bij apotheken. De overheid heeft regels opgesteld voor het 
bereiden van koolteerzalven waarbij strenge voorzorgsmaatregelen getroffen moeten 
worden. Dit heeft als gevolg dat de zalven niet meer door alle apothekers worden 
bereid. Om de huidige rol van koolteer in de behandeling van psoriasis en eczeem te 
evalueren, hebben we onder alle Nederlandse en Vlaamse dermatologen een 
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risicofactoren voor blaaskanker. Er werd geen associatie gevonden tussen het 
gebruik van koolteer en blaaskanker. 
Risico op kanker bij patiënten met psoriasis of eczeem
Psoriasis en eczeem zijn veel voorkomende, inflammatoire huidziekten waarin een 
hyperreactief immuunsysteem tot chronische inflammatie leidt. Door de chronische 
stimulatie van cellen van het immuunsysteem, hebben deze patiënten mogelijk een 
verhoogd risico op kanker. In veel studies is het risico op kanker bij patiënten met 
psoriasis en eczeem onderzocht waarbij in de meerderheid van deze studies een 
verhoogd risico op kanker werd gevonden. In deze studies waren veel patiënten 
behandeld met carcinogene middelen zoals cyclosporine en PUVA waardoor het niet 
mogelijk was om het aandeel van het effect van deze behandelingen op het risico op 
kanker uit te filteren.
 In hoofdstuk 5 wordt de cohort studie beschreven waarin het risico op kanker 
werd onderzocht bij patiënten met psoriasis en eczeem. Het aantal gediagnosticeer-
de tumoren in het cohort werd vergeleken met de algemene bevolking. Om het aantal 
tumoren in de algemene bevolking te berekenen, werden incidentiecijfers (gestratifi-
ceerd voor geslacht, leeftijd en kalenderperiode) van de Nederlandse Kankerregi-
stratie gebruikt. Doordat informatie werd verzameld over alle middelen waarmee 
patiënten werden behandeld, was het mogelijk om een groep patiënten te selecteren 
die alleen werden behandeld met emollientia en/of lokale corticosteroïden. Hierdoor 
was het mogelijk om het intrinsieke (therapieonafhankelijke) risico op kanker in deze 
subgroep te onderzoeken.
 Het risico op kanker in het gehele cohort van patiënten met psoriasis en eczeem 
was licht verhoogd. Ook werd er een licht verhoogd risico op kanker gevonden in de 
subgroep van patiënten die alleen met lokale corticosteroïden werden behandeld. 
Deze studie heeft laten zien dat patiënten met psoriasis en eczeem een licht verhoogd 
risico op kanker hebben, onafhankelijk van behandeling. Een mogelijke verklaring 
hiervoor is de chronische stimulatie van het immuunsysteem bij deze patiënten. 
Metabolisatie van PAKs in de huid
Koolteerzalven bevatten hoge concentraties polycyclische aromatische koolwater-
stoffen (PAKs). Bij dermatologisch gebruik is de huid één van de belangrijkste 
opnameroutes van deze PAKs. 1-hydroxypyreen (1-OHP), de belangrijkste metaboliet 
van pyreen, kan worden gebruikt als biomarker voor dermale opname en omzetting 
van PAKs.
 Psoriasis wordt gekenmerkt door hyperproliferatie van de epidermis waardoor 
deze verdikt is. De  barrière functie raakt hierbij verstoord en er treedt verandering op 
van  de permeabiliteit van de huid. Hierdoor zou de metabolisatie van PAKs in de 
huid bij psoriasis kunnen verschillen van gezonde huid. Het carcinogene effect van 
enquête uitgevoerd. In hoofdstuk 3 worden de resultaten van deze studie beschreven. 
De enquête werd uitgevoerd onder Nederlandse en Vlaamse dermatologen om een 
indruk te krijgen over mogelijke verschillen en overeenkomsten in voorschrijfgedrag 
tussen deze twee landen. Uit de resultaten van deze studie bleek dat bijna alle 
dermatologen topicale corticosteroïden, vitamine D3 analogen en calcineurine-inhi-
bitoren voorschrijven. De meerderheid van de dermatologen schrijft daarnaast ook 
nog steeds koolteerzalven voor. Wij concludeerden uit deze resultaten dat 
koolteerzalven nog steeds een plaats hebben in de behandeling van psoriasis en 
eczeem. 
Risico op kanker na behandeling met koolteer
Ondanks het ontbreken van goed bewijs op een verhoogd risico op kanker na het 
gebruik van koolteer, wordt het minder voorgeschreven door dermatologen. Het zou 
echter voorbarig zijn om het gebruik van koolteer uit te bannen voordat dat het risico 
op kanker na koolteer goed is onderzocht. Daarom werd in 2003 de LATER-studie 
(Late effecten van koolteer behandeling in patiënten met eczeem of psoriasis; de 
Radboud studie) gestart. In hoofdstuk 4.1 worden de resultaten van deze studie 
beschreven waarin 13.200 patiënten, gediagnosticeerd met psoriasis of eczeem 
tussen 1960 en 1990, werden geïncludeerd. Informatie over de huidziekte, 
behandelingen, risicofactoren voor kanker en het voorkomen van kanker werden 
verzameld met behulp van medische dossiers, vragenlijsten en medische registraties 
(Nederlandse Kankerregistratie en de Doodsoorzaken Registratie van het Centraal 
Bureau voor de Statistiek). Patiënten die werden behandeld met koolteer werden 
vergeleken met patiënten die alleen met lokale corticosteroïden of emollientia werden 
behandeld. Voor deze referentiegroep werd gekozen omdat het gebruik van lokale 
corticosteroïden en emollientia niet geassocieerd is met kanker. Er werd geen 
verhoogd risico gevonden op huidkanker of interne tumoren na het gebruik van 
koolteer. Uit deze resultaten concludeerden wij dat het gebruik van koolteer bij de 
behandeling bij psoriasis en eczeem veilig is. 
Nadat koolteer op de huid is aangebracht, wordt het geabsorbeerd en gemetaboli-
seerd. Tijdens dit proces worden diverse metabolieten van koolteer in de urine 
uitgescheiden waardoor er theoretisch een verhoogd risico op blaaskanker zou 
kunnen zijn. Het risico op blaaskanker bij patiënten met psoriasis en eczeem is in 
enkele studies onderzocht, maar in geen enkele studie werd de relatie tussen 
behandeling met koolteer en blaaskanker specifiek onderzocht. In een case-controle 
studie, beschreven in hoofdstuk 4.2, werd de associatie tussen het dermatologisch 
gebruik van koolteer en blaaskanker bestudeerd. 1387 patiënten met blaaskanker en 
3527 controles werden geïncludeerd. Vragenlijsten werden gebruikt om informatie te 
verzamelen over het gebruik van koolteer, het voorkomen van huidziekten en 
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koolteer zou door de verstoorde permeabiliteit van de huid en een mogelijk andere 
metabolisatie van PAKs anders kunnen zijn bij patiënten met psoriasis ten opzichte 
van gezonde vrijwilligers. 
 Om mogelijke verschillen in dermale absorptie en metabolisatie van PAKs na 
koolteer blootstelling te onderzoeken, werd een studie uitgevoerd bij tien patiënten 
met psoriasis en tien gezonde vrijwilligers. Hoofdstuk 6 beschrijft de resultaten van 
deze toxicologische studie. Huidbiopten werden afgenomen vóór het aanbrengen 
van koolteer en nadat de koolteerzalf na 96 uur blootstelling werd verwijderd. Uit de 
biopten werd DNA geïsoleerd om het gehalte aan PAK-DNA adducten te bepalen. 
Urinemonsters werden verzameld vóór het aanbrengen van de koolteerzalf, tijdens 
de onderzoeksperiode en na 96 uur blootstelling. In de urinemonsters werd het 
gehalte aan 1-hydroxypyreen bepaald. 48 uur na blootstelling aan koolteerzalf werd 
een statistisch significant hogere 1-OHP excretie gevonden bij de gezonde vrijwilligers 
ten opzichte van de patiënten met psoriasis. Vóór het aanbrengen van koolteer was 
het PAK-DNA adducten gehalte in beide onderzoeksgroepen gelijk, maar na 96 uur 
blootstelling was het gehalte aan PAK-DNA adducten hoger bij de gezonde 
vrijwilligers dan bij de psoriasis patiënten. Deze resultaten suggereren een lager 
carcinogeen risico bij psoriasis door een verminderde absorptie en bio-activatie van 
PAKs. Er is meer onderzoek nodig om de gevonden resultaten op cellulair niveau te 
kunnen verklaren.
Conclusies
De belangrijkste conclusies van dit proefschrift zijn: 
- Koolteer is nog steeds een belangrijke therapeutische optie bij de behandeling 
van psoriasis en eczeem (hoofdstuk 3)
- De belangrijkste redenen voor het verminderd gebruik van koolteer zijn de 
moeizame verkrijging van koolteer bij apotheken en de mogelijke carcinogeniteit 
van koolteer (hoofdstuk 3)
- Patiënten met psoriasis en eczeem hebben geen verhoogd risico op kanker na 
behandeling met koolteer (hoofdstuk 4)
- Dermatologisch gebruik van koolteer is niet geassocieerd met een verhoogd 
risico op blaaskanker (hoofdstuk 4)
- Patiënten met psoriasis of eczeem hebben een licht verhoogd risico op kanker, 
onafhankelijk van behandeling (hoofdstuk 5)
- Opname, beschikbaarheid en bio-activiteit van PAKs in patiënten met psoriasis 
verschilt van gezonde vrijwilligers (hoofdstuk 6)
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Een proefschrift schrijven doe je zeker niet alleen. Ik wil daarom iedereen bedanken 
die op enigerlei wijze bijgedragen hebben aan de totstandkoming van dit proefschrift. 
Een aantal mensen wil ik persoonlijk bedanken voor hun betrokkenheid bij mijn pro-
motietraject.
Bart Kiemeney, allereerst een woord van dank voor jou. Ik heb veel bewondering voor 
al het succes wat in de afgelopen jaren onder jouw leiding tot stand is gekomen. 
Ondanks je drukke agenda, maakte je altijd tijd vrij voor overleg of om snel en 
uitgebreid te reageren op de concepten van mijn artikelen.
Katja Aben, je was mijn directe begeleidster tijdens mijn promotieonderzoek en je 
hebt het KWF-project voor mijn promotieonderzoek voor het grootste deel 
geschreven. Vanuit de schoolbank was het voor mij even wennen in onderzoeksland, 
maar gelukkig kon ik voor goede raad en ideeën altijd bij jou terecht. Hartelijk dank 
voor je goede begeleiding.  
Pieter van der Valk, via jou heb ik in 2002 mijn keuze coschap op de afdeling 
Dermatologie geregeld en hiermee werd de basis voor mijn latere onderzoek en 
opleiding gelegd. Tijdens mijn latere onderzoeksstage vertelde je over het KWF-on-
derzoeksproject waarvoor subsidie was verkregen. Jouw advies om te solliciteren 
heeft goed uitgepakt! Je bent altijd met veel enthousiasme bij mijn onderzoek 
betrokken geweest. Heel veel dank voor de fijne samenwerking.  
Peter van de Kerkhof,  jouw enthousiasme en positieve benadering zorgde ervoor dat 
ik na een overleg altijd weer positief aan de slag kon met mijn onderzoek. Na de 
hiërarchische benadering die ik vanuit Antwerpen gewend was, was jouw 
laagdrempelige benadering voor mij een verademing. Hartelijk dank voor je 
begeleiding tijdens het onderzoek en mijn opleiding.
Ursula, een heel groot woord van dank voor jou, want wat heb jij veel werk verricht 
voor mijn onderzoek! Je hebt vele kilometers afgelegd om statusonderzoek te doen 
in de “bunker” in Schaarsbergen. Toen we je daarna nog vroegen om ook nog “even” 
statusonderzoek te gaan doen in Groningen, ging je ook daar aan de slag. Je hebt 
vast vaak gedroomd over muren van medische dossiers.  Daarna volgde de fase van 
het versturen en verwerken van de vragenlijsten. Je werkte altijd zeer precies en 
gestructureerd; kortom de ideale onderzoekassistente! Heel fijn dat je als afronding 
van mijn onderzoek vandaag mijn paranimf bent. 
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Tamara, dank jullie wel voor de leuke tijd. Alle stafleden, arts-assistenten, arts-onder-
zoekers, verpleging, administratie en andere medewerkers van de afdeling 
Dermatologie wil ik bedanken voor de prettige samenwerking. 
Mijn huidige collega’s van de vakgroep Dermatologie van het Streekziekenhuis 
Koningin Beatrix in Winterswijk wil ik bedanken voor de ontzettende fijne werksfeer en 
de interesse die jullie steeds hebben getoond in de voortgang van dit proefschrift. De 
overstap van het Radboud naar Winterswijk is dankzij jullie heel soepel verlopen.
Lieve vrienden, wellicht dat het nu met de promotie en dit proefschrift een beetje 
duidelijk is geworden wat mijn onderzoek allemaal inhield. Bedankt voor jullie 
getoonde interesse voor mijn onderzoek en werkzaamheden, al was het juist fijn dat 
het met jullie meestal niet over mijn promotieonderzoek ging. Heel fijn dat jullie er 
vandaag bij zijn!   
Lieve schoonfamilie: André & Riet, Pim & Marjan, Tom en Luuk en Kees & Saskia. 
Jullie waren en zijn altijd heel geïnteresseerd in al mijn bezigheden. Veel dank voor 
jullie betrokkenheid bij mijn promotietraject en voor de nodige afleiding tijdens alle 
bezoekjes in de afgelopen jaren.  
In het bijzonder wil ik natuurlijk ook mijn ouders bedanken. Lieve papa en mama, 
jullie hebben altijd voor mij klaargestaan en doen dat nog steeds. Ontzettend bedankt 
voor jullie niet aflatende steun op alle gebied! Hopelijk worden we weer snel “herenigd” 
in de Achterhoek. 
Lieve zus Roël en Maarten, vanwege de afstand zien we elkaar niet zo vaak, maar 
aan telefoon kan ook morele support worden gegeven. Dat gebeurt dan wederzijds 
ook regelmatig! Wat fijn om het afronden van mijn promotieonderzoek vandaag met 
jullie te kunnen delen.
Tot slot Rens. Natuurlijk is de laatste alinea van dit dankwoord voor jou want je hebt 
als geen ander meegeleefd met mijn promotie. Eindelijk is het proefschrift dan af en 
kunnen we dit “project” afronden. Vanaf nu blijft er dus weer meer tijd over voor jou 
en voor Chiel, het allerliefste mannetje van de hele wereld!
Denise, vanaf het eerste moment van onze kennismaking op het “C10 eiland”, konden 
we het al goed met elkaar vinden. In de loop van de tijd hebben we veel patiëntgere-
lateerde zaken, maar vooral ook “overige zaken” besproken! Je hebt het voor elkaar 
gekregen om tijdens je opleiding je hele promotieonderzoek uit te voeren en af te 
ronden, heel knap! Bedankt dat je vandaag mijn paranimf bent en veel succes met 
het verdedigen van jouw proefschrift. Hopelijk blijven we elkaar de komende jaren 
nog heel vaak zien.
Alle student-assistenten die hebben geholpen met het statusonderzoek en het 
verwerken van de vragenlijsten, hartelijk dank voor jullie hulp.
Tijdens het statusonderzoek in het Radboud bleek dat er onvoldoende patiënten 
geïncludeerd konden worden voor ons cohort. Daarom werd ook statusonderzoek 
gedaan in de archieven van de afdelingen Dermatologie van het Universitair Medisch 
Centrum Groningen en het Canisius-Wilhelmina Ziekenhuis in Nijmegen. Professor 
Coenraads en Dr. Alkemade, bedankt voor jullie medewerking en samenwerking 
tijdens het onderzoek.   
Op de afdeling Epidemiologie, Biostatistiek en HTA, inmiddels Department for Health 
Evidence, heb ik een hele fijne onderzoekstijd gehad. Er werd hard gewerkt, maar er 
was ook tijd voor gezelligheid. De cake-van-de week, de gezellige lunchpauzes en 
sociale activiteiten hebben zeker positief bijgedragen aan mijn promotietijd. Hans en 
Marijn, het was erg gezellig om met jullie in de SoA-commissie te zitten. We hebben 
vele leuke borrels en andere activiteiten georganiseerd. Reini, bedankt voor de 
gezellige tijd en fijn dat we elkaar nog steeds een paar keer per jaar zien om bij te 
praten tijdens een gezellig etentje. Hans, we hebben een beetje hetzelfde tempo 
aangehouden. Nu mijn “project” is afgerond, is jouw renovatieproject ook afgerond. 
Erik, dank voor je hulp bij het programmeren van de SPSS- en SAS-programma’s die 
ik nodig had voor de statistische analyses. Voor mij soms onbegrijpelijk hoe je het 
voor elkaar kreeg, maar het werkte altijd! Wim, als dorpsgenoten hebben we vaak 
samen gereden naar het werk. Op je werkplek aan het begin van de gang op de 3e 
verdieping had je altijd tijd voor mijn vragen en een gezellig praatje. Ook toen ik was 
“verhuisd” naar de afdeling Dermatologie kon ik nog altijd bij jou terecht als mijn 
SPSS- of SAS programma’s weer eens kuren hadden. Alle andere collega’s van de 
afdeling wil ik ook bedanken voor de prettige werksfeer op de afdeling.  
Tijdens mijn opleiding op de afdeling Dermatologie heb ik vele kamergenoten gehad. 
Op C10 begon ik samen met Denise, Maartje en Demia. Dit was een erg leuke tijd! 
Ook onze etentjes waren en zijn altijd erg gezellig en hopelijk blijven we dit de 
komende jaren nog regelmatig doen. Ook latere kamergenoten John, Michelle en 
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